

Table D1. Evidence table for observational studies

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Badart-Smook, et al., 1997⁴⁷</p> <p>Study dates: NR</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: NR</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 610 Pregnant withdrawals 240 Pregnant completers 370</p> <p>Pregnant age: 29 (4)</p> <p>Race of Mother: White European (100)</p>	<p>Inclusion Criteria: White race, intention to give birth to the baby in one of the three hospitals involved in the study</p> <p>Exclusion Criteria: Women with diastolic blood pressure of 90mm or higher, women suffering from any metabolic, cardiovascular, neurological, or renal disorder</p>	<p>Adjustments: Maternal(pregnancy) body weight, height, age, smoking habits, education, parity, and sex of the infant were included in each multiple regression model as possible confounding factors; except for the regression equation with gestational age as a dependent variable, gestational age at birth was also added as a confounder</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
<p>Badart-Smook 1997⁴⁷</p>	<p>Birth weight N Total: 370</p> <p>Length of gestation N Total: 370</p>		<p>Sum of n-3 PUFAs+AA n-3 Measure: FFQ</p> <p>Sum of n-3 PUFAs+AA n-3 Measure: FFQ</p>			

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Bakker, et al., 2003¹⁶³</p> <p>Study name: Maastricht Essential Fatty Acid Birth (MEFAB) Cohort</p> <p>Study dates: Recruitment December 1990 to January 1994</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 7 years</p> <p>Original, same study, or follow-up studies: Bakker, 2009¹³⁴ and two articles in original report: Ghys, 2002 and AI, 1995</p>	<p>Study Population: Healthy infants</p> <p>Infants enrolled 750 Infants withdrawals 444 Infants completers 306</p> <p>Pregnant age: 29.8 (4.1)</p> <p>Infant age: birth</p> <p>Race of Mother: White European (100)</p>	<p>Inclusion Criteria: 750 Caucasian children, 7 y old, born between December 1990 and January 1994 in the course of an earlier study on maternal and neonatal LCPUFA status and pregnancy outcome</p> <p>Exclusion Criteria: Not reported</p>	<p>Adjustments: Social class, maternal intelligence, parenting skills, maternal smoking and drinking habits during pregnancy, breastfeeding duration, and the child's sex, birth order and birthweight</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Bakker 2003 ¹⁶³	Cognitive function K-ABC Mental	7 years	AA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt	All	Coefficient Estimate: -0.223 95% CI(-1.051,-0.605)	
	Cognitive function K-ABC Mental N Total: 306	7 years	DHA n-3 Measure: Umbilical plasma n-3 Units: % wt/wt	All	Coefficient Estimate: -0.517 95% CI(-1.471, -0.437)	
	Cognitive function K-ABC Sequential	7 years	AA n-3 Measure: Umbilical plasma	All	Coefficient Estimate: 0.035 95% CI(-0.886, -0.956)	
	Cognitive function K-ABC Sequential	7 years	DHA n-3 Measure: Umbilical plasma	All	Coefficient Estimate: -0.072 95% CI(-1.104, - 0.960)	
	Cognitive function K-ABC Simultaneous	7 years	AA n-3 Measure: Umbilical plasma	All	Coefficient Estimate: -0.34 95% CI(-1.156, 0.476)	
	Cognitive function K-ABC Simultaneous	7 years	DHA n-3 Measure: Umbilical plasma	All	Coefficient Estimate: -0.61 95% CI(-1.557, -0.337)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Bakker, et al., 2009¹³⁴</p> <p>Study dates: 12/90-1/94</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 7 years</p> <p>Original, same study, or follow-up studies: Bakker, 2003⁸⁰ and two articles in original report: Ghys, 2002 and AI, 1995</p>	<p>Study Population: Healthy infants</p> <p>Infants enrolled 750 Infants withdrawals 444 Infants completers 306</p> <p>Pregnant age: 29.8 (4.1)</p> <p>Infant age: gestational age: boys: 39.8; girls 40.0 (boys 1.7; girls 1.4)</p> <p>Race of Mother: White European (100)</p>	<p>Inclusion Criteria: 750 Caucasian children of 7 y old, born between December 1990 and January 1994 in the course of an earlier study on maternal and neonatal LCPUFA status and pregnancy outcome</p> <p>Exclusion Criteria: Not reported</p>	<p>Adjustments: Gender, cognitive function, gestational age, age at measurement</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Bakker 2009 ¹³⁴	Maastricht Motor test quality score N Total: 306	7 years	AA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.052
	Maastricht Motor test quality score N Total: 306	7 years	DHA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.01
	Maastricht Motor test quantity score N Total: 306	7 years	AA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.78
	Maastricht Motor test quantity score N Total: 306	7 years	DHA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.30
	Maastricht Motor test total score N Total: 306	7 years	AA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.069
	Maastricht Motor test total score N Total: 306	7 years	DHA n-3 Measure: Umbilical plasma n-3 Units: %wt/wt		Coefficient	P value: P=0.01

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Bernard, et al., 2013 ⁸⁹ Study name: EDEN Study dates: Recruitment 2003 to 2005 Study design: Observational prospective Location: NR Funding source / conflict: Industry, Government Follow-up: 2 and 3 years Original, same study, or follow-up studies: Drouillet, 2009 ⁸⁰	Study Population: Healthy pregnant women Pregnant enrolled 2,002 Pregnant completers 1,882 Infants enrolled 1,882 Infants completers 1,510 Pregnant age: 29.2 years (at conception) (4.8 years) NR Infant age: < 24 weeks gestation (NR) NR Race of Mother: NR (100)	Inclusion Criteria: < 24 weeks amenorrhea Exclusion Criteria: multiple pregnancies, known diabetes before pregnancy, illiteracy, and intention to move outside the region in the next 3 years	Adjustments: Center, child gender & age, gestational age, maternal age, obesity, energy intake, tobacco & alcohol consumption, parental education & income, first born, main daytime caregiver, and frequency of maternal stimulations

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Bernard, 2013 ⁸⁹	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	(LC)PUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.19 95% CI(-0.76, 0.38)	P value: 0.51
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.09 95% CI(-29.53, 29.35)	P value: 1
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 3.29 95% CI(-8.41, 14.99)	P value: 0.58
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 7.48 95% CI(-10.51, 25.47)	P value: 0.42
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 15.28 95% CI(-18.63, 49.19)	P value: 0.38
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.23 95% CI(-0.82, 0.36)	P value: 0.45
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 3.61 95% CI(-4.17, 11.39)	P value: 0.36
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.22 95% CI(-0.81, 0.37)	P value: 0.45
	Ages and Stages Questionnaire - Breastfed children N Total: 786	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.63 95% CI(-1.39, 0.13)	P value: 0.11

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	(LC)PUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.33 95% CI(-2.58, -0.08)	P value: 0.04
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -104.25 95% CI(-162.11, -46.39)	P value: 0.001
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.39 95% CI(-31.22, 26.44)	P value: 0.87
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.77 95% CI(-49.10, 45.56)	P value: 0.94
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 24.51 95% CI(-60.08, 109.10)	P value: 0.57
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.34 95% CI(-2.65, -0.03)	P value: 0.05
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.43 95% CI(-21.52, 16.66)	P value: 0.8
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.37 95% CI(-2.68, -0.06)	P value: 0.04
	Ages and Stages Questionnaire - Never-breastfed children N Total: 270	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.52 95% CI(-3.01, -0.03)	P value: 0.05
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	(LC)PUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.13 95% CI(-2.21, -0.05)	P value: 0.04
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -33.93 95% CI(-83.64, 15.78)	P value: 0.18
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 13.84 95% CI(-10.21, 37.89)	P value: 0.26
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 6.14 95% CI(-32.79, 45.07)	P value: 0.76
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 13.98 95% CI(-57.56, 85.52)	P value: 0.7
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.23 95% CI(-2.37, -0.09)	P value: 0.03
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 7.02 95% CI(-9.13, 23.17)	P value: 0.39

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.24 95% CI(-2.36, -0.12)	P value: 0.03
	Communicative Development Inventory - Never-breastfed children N Total: 309	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.13 95% CI(-3.40, -0.86)	P value: 0.001
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	(LC)PUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.23 95% CI(-0.34, 0.80)	P value: 0.43
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 6.29 95% CI(-22.56, 35.14)	P value: 0.67
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.77 95% CI(-14.65, 9.11)	P value: 0.65
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -3.63 95% CI(-21.72, 14.46)	P value: 0.69
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -8.55 95% CI(-42.77, 25.67)	P value: 0.62
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.25 95% CI(-0.34, 0.84)	P value: 0.4
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.23 95% CI(-10.07, 5.61)	P value: 0.58
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.25 95% CI(-0.34, 0.84)	P value: 0.4
	Communicative Development Inventory -Breastfed children N Total: 901	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.38 95% CI(-0.40, 1.16)	P value: 0.34
	Motor ability N Total: 257	3 years	(LC)PUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.17 95% CI(-0.6924, 1.0324)	
	Motor ability N Total: 257	3 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 5.07 95% CI(3.8744, 6.2656)	
	Motor ability N Total: 257	3 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.3 95% CI(-2.8288, 0.2288)	
	Motor ability N Total: 257	3 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -4.35 95% CI(-5.526, -3.174)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Motor ability N Total: 257	3 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -10.55 95% CI(-11.4908, -9.6092)	
	Motor ability N Total: 257	3 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.17 95% CI(-0.6924, 1.0324)	
	Motor ability N Total: 257	3 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.72 95% CI(-2.896, -0.544)	
	Motor ability N Total: 257	3 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.17 95% CI(-0.6728, 1.0128)	
	Motor ability N Total: 257	3 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.49 95% CI(0.3724, 0.6076)	
	Motor ability N Total: 746	3 years	(LC)PUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.1 95% CI(-0.1156, 0.3156)	
	Motor ability N Total: 746	3 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -7.67 95% CI(-19.3124, 3.9724)	
	Motor ability N Total: 746	3 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.29 95% CI(-4.4336, 5.0136)	
	Motor ability N Total: 746	3 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -3.26 95% CI(-10.5316, 4.0116)	
	Motor ability N Total: 746	3 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -9.8 95% CI(-23.5004, 3.9004)	
	Motor ability N Total: 746	3 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.12 95% CI(-0.1152, 0.3552)	
	Motor ability N Total: 746	3 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.11 95% CI(-4.2264, 2.0064)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Motor ability N Total: 746	3 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.12 95% CI(-0.1152, 0.3552)	
	Motor ability N Total: 746	3 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.3 95% CI(-0.0136, 0.6136)	
	Neurological development N Total: 270	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -104.25 95% CI(-162.1092, -46.3908)	
	Neurological development N Total: 270	3 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -104.25 95% CI(-162.1092, -46.3908)	
	Neurological development N Total: 270	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.39 95% CI(-31.2216, 26.4416)	
	Neurological development N Total: 270	3 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -2.39 95% CI(-31.2216, 26.4416)	
	Neurological development N Total: 270	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.77 95% CI(-49.104, 45.564)	
	Neurological development N Total: 270	3 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.77 95% CI(-49.104, 45.564)	
	Neurological development N Total: 270	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 24.51 95% CI(-60.0836, 109.1036)	
	Neurological development N Total: 270	3 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 24.51 95% CI(-60.0836, 109.1036)	
	Neurological development N Total: 270	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.34 95% CI(-2.6532, -0.0267999999999999)	
	Neurological development N Total: 270	3 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.34 95% CI(-2.6532, -0.0267999999999999)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Neurological development N Total: 270	3 years	LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.33 95% CI(-2.5844, -0.0756000000000001)	
	Neurological development N Total: 270	3 years	LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.33 95% CI(-2.5844, -0.0756000000000001)	
	Neurological development N Total: 270	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.43 95% CI(-21.5204, 16.6604)	
	Neurological development N Total: 270	3 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -2.43 95% CI(-21.5204, 16.6604)	
	Neurological development N Total: 270	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.37 95% CI(-2.6832, -0.0568)	
	Neurological development N Total: 270	3 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.37 95% CI(-2.6832, -0.0568)	
	Neurological development N Total: 270	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.52 95% CI(-3.0096, -0.0304)	
	Neurological development N Total: 270	3 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.52 95% CI(-3.0096, -0.0304)	
	Neurological development N Total: 309	2 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -33.93 95% CI(-83.6356, 15.7756)	
	Neurological development N Total: 309	2 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -33.93 95% CI(-83.6356, 15.7756)	
	Neurological development N Total: 309	2 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 13.84 95% CI(-10.2092, 37.8892)	
	Neurological development N Total: 309	2 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 13.84 95% CI(-10.2092, 37.8892)	
	Neurological development N Total: 309	2 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 6.14 95% CI(-32.7856, 45.0656)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Neurological development N Total: 309	2 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 6.14 95% CI(-32.7856, 45.0656)	
	Neurological development N Total: 309	2 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 13.98 95% CI(-57.56, 85.52)	
	Neurological development N Total: 309	2 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 13.98 95% CI(-57.56, 85.52)	
	Neurological development N Total: 309	2 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.23 95% CI(-2.3668, - 0.0932000000000002)	
	Neurological development N Total: 309	2 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.23 95% CI(-2.3668, - 0.0932000000000002)	
	Neurological development N Total: 309	2 years	LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.13 95% CI(-2.208, - 0.0519999999999998)	
	Neurological development N Total: 309	2 years	LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.13 95% CI(-2.208, - 0.0519999999999998)	
	Neurological development N Total: 309	2 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 7.02 95% CI(-9.1304, 23.1704)	
	Neurological development N Total: 309	2 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 7.02 95% CI(-9.1304, 23.1704)	
	Neurological development N Total: 309	2 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -1.24 95% CI(-2.3572, -0.1228)	
	Neurological development N Total: 309	2 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -1.24 95% CI(-2.3572, -0.1228)	
	Neurological development N Total: 309	2 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.13 95% CI(-3.404, -0.856)	
	Neurological development N Total: 309	2 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -2.13 95% CI(-3.404, -0.856)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Neurological development N Total: 786	3 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.09 95% CI(-29.5292, 29.3492)	
	Neurological development N Total: 786	3 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -0.09 95% CI(-29.5292, 29.3492)	
	Neurological development N Total: 786	3 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 3.29 95% CI(-8.4112, 14.9912)	
	Neurological development N Total: 786	3 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 3.29 95% CI(-8.4112, 14.9912)	
	Neurological development N Total: 786	3 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 7.48 95% CI(-10.5128, 25.4728)	
	Neurological development N Total: 786	3 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 7.48 95% CI(-10.5128, 25.4728)	
	Neurological development N Total: 786	3 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 15.28 95% CI(-18.628, 49.188)	
	Neurological development N Total: 786	3 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 15.28 95% CI(-18.628, 49.188)	
	Neurological development N Total: 786	3 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.23 95% CI(-0.818, 0.358)	
	Neurological development N Total: 786	3 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -0.23 95% CI(-0.818, 0.358)	
	Neurological development N Total: 786	3 years	LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.19 95% CI(-0.7584, 0.3784)	
	Neurological development N Total: 786	3 years	LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -0.19 95% CI(-0.7584, 0.3784)	
	Neurological development N Total: 786	3 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 3.61 95% CI(-4.1712, 11.3912)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Neurological development N Total: 786	3 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 3.61 95% CI(-4.1712, 11.3912)	
	Neurological development N Total: 786	3 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.22 95% CI(-0.808, 0.368)	
	Neurological development N Total: 786	3 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -0.22 95% CI(-0.808, 0.368)	
	Neurological development N Total: 786	3 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -0.63 95% CI(-1.3944, 0.1344)	
	Neurological development N Total: 786	3 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -0.63 95% CI(-1.3944, 0.1344)	
	Neurological development N Total: 901	2 years	AA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 6.29 95% CI(-22.5612, 35.1412)	
	Neurological development N Total: 901	2 years	AA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 6.29 95% CI(-22.5612, 35.1412)	
	Neurological development N Total: 901	2 years	ALA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.77 95% CI(-14.6476, 9.1076)	
	Neurological development N Total: 901	2 years	ALA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -2.77 95% CI(-14.6476, 9.1076)	
	Neurological development N Total: 901	2 years	DHA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -3.63 95% CI(-21.7208, 14.4608)	
	Neurological development N Total: 901	2 years	DHA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -3.63 95% CI(-21.7208, 14.4608)	
	Neurological development N Total: 901	2 years	EPA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -8.55 95% CI(-42.7716, 25.6716)	
	Neurological development N Total: 901	2 years	EPA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -8.55 95% CI(-42.7716, 25.6716)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Neurological development N Total: 901	2 years	LA n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.25 95% CI(-0.338, 0.838)	
	Neurological development N Total: 901	2 years	LA n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.25 95% CI(-0.338, 0.838)	
	Neurological development N Total: 901	2 years	LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.23 95% CI(-0.3384, 0.7984)	
	Neurological development N Total: 901	2 years	LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.23 95% CI(-0.3384, 0.7984)	
	Neurological development N Total: 901	2 years	n-3 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: -2.23 95% CI(-10.07, 5.61)	
	Neurological development N Total: 901	2 years	n-3 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: -2.23 95% CI(-10.07, 5.61)	
	Neurological development N Total: 901	2 years	n-6 LCPUFAs n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.25 95% CI(-0.338, 0.838)	
	Neurological development N Total: 901	2 years	n-6 LCPUFAs n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.25 95% CI(-0.338, 0.838)	
	Neurological development N Total: 901	2 years	n-6:n-3 n-3 Measure: FFQ n-3 Units: g/d		Coefficient Estimate: 0.38 95% CI(-0.404, 1.164)	
	Neurological development N Total: 901	2 years	n-6:n-3 n-3 Measure: Maternal food frequency questionnaire n-3 Units: g/d	All	Coefficient Estimate: 0.38 95% CI(-0.404, 1.164)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Bouwstra, et al., 2006¹³³</p> <p>Study dates: 1997-1999</p> <p>Study design: NR</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Industry</p> <p>Follow-up: 3 months</p> <p>Original, same study, or follow-up studies: Bouwstra, 2003⁶²</p>	<p>Study Population: Healthy infants</p> <p>Infants enrolled 317 Infants completers 269</p> <p>Pregnant age: 30 (4.3)</p> <p>Infant age: 3 months (NR)</p> <p>Race of Mother: White European (100)</p>	<p>Inclusion Criteria: All infants were born at 37–42 wk of gestation, had a native West European origin, and were born between February 1997 and October 1999.</p> <p>Exclusion Criteria: children with a congenital disorder interfering with adequate functioning in daily life, children from multiple births, children whose mother did not master the Dutch language or had significant illness or disability, and adopted and fostered children</p>	<p>Adjustments: Type of postnatal feeding and potential confounders such as the postnatal age of the infant at GM assessment, paternal smoking, and the total Obstetric Optimality Score</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Bouwstra 2003 ¹³³	General movement (mildly abnormal) N Total: 269	3 months	AA n-3 Measure: umbilical artery	All	Standardized coefficients Estimate: 0.81 95% CI(0.68, 0.98)	
	General movement (mildly abnormal) N Total: 269	3 months	DHA deficiency index n-3 Measure: umbilical artery	All	Standardized coefficients Estimate: 2 95% CI(0.73, 5.2)	
	General movement (mildly abnormal) N Total: 269	3 months	DHA n-3 Measure: umbilical artery	All	Standardized coefficients Estimate: 0.74 95% CI(0.48, 1.1)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Brantsaeter, et al., 2012⁸¹</p> <p>Study name: Norwegian Mother and Child Cohort Study (MoBa)</p> <p>Study dates: 2002-2009</p> <p>Study design: Observational prospective</p> <p>Location: Norway</p> <p>Funding source / conflict: Government</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 76218 Pregnant completers 62099</p> <p>Race of Mother: NR</p>	<p>Inclusion Criteria: first participation for women with multiple participation in MoBa and women with singleton births.</p> <p>Exclusion Criteria: participants with a pregnancy duration <28 weeks or >42 weeks (n=628), if the birth weight of the baby had not been recorded or if the birth weight was, <600 g (n = 35). We also excluded participants who had not given birth to a live baby (n 153). Lastly, we excluded women having improbable energy intakes, i.e. energy intake , >4.5 MJ or .<20 MJ (n 1063)</p>	<p>Adjustments: Adjusted for maternal age, height, pre-pregnant BMI, parity, pregnancy duration, maternal education, smoking status, mother tongue other than Norwegian and total energy intake, and with intakes of seafood/seafood items and supplementary n-3 mutually adjusted</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Brantsaeter 2012 ⁸¹	Birth weight N Total: 61387		n-3 supplement n-3 Measure: FFQ n-3 Units: g/day	0 (No) N Quantile: NR N Cases: NR		
	Birth weight N Total: 61387		n-3 supplement n-3 Measure: FFQ n-3 Units: g/day	0.40 - 6.9 N Quantile: NR N Cases: NR	0.74 95% CI(-7.6, 9.07)	
	Birth weight N Total: 61387		n-3 supplement n-3 Measure: FFQ n-3 Units: g/day	< 0.39 N Quantile: NR N Cases: NR	-2.03 95% CI(-10.4, 6.29)	
	Birth weight N Total: 61387		n-3 supplement n-3 Measure: FFQ n-3 Units: g/day	Per g increase N Quantile: NR N Cases: NR	Coefficient Estimate: 0.53 95% CI(-3.25, 4.31)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Chong, et al., 2015⁹⁵</p> <p>Study dates: 2009-2010</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Industry, Government</p> <p>Follow-up: 3 months postpartum</p>	<p>Study Population: Healthy pregnant women Postpartum women</p> <p>Pregnant enrolled 997 Pregnant completers 698</p> <p>Pregnant age: NR (NR)</p> <p>Race of Mother: Asian (100)</p>	<p>Inclusion Criteria: Within range of 18-50 years, recruited from 2 major public maternity units in NUH and KKH. Were Singaporean citizens or permanent resident of Chinese, Malay, Indian ethnicity with parents of homogeneous ethnic background, with the intention to deliver in the two hospitals and residing in Singapore for next 5 years and willing to donate birth tissues including cord, placenta, cord blood at delivery</p> <p>Exclusion Criteria: pre-existing health conditions such as type 1 diabetes, depression, or mental health related disorders self-reported during recruitment</p>	<p>Adjustments: Adjusted for ethnicity, parity, education level, marital status, maternal body mass index at 26-28 week's gestation, maternal age, employment status, obstetric and neonatal complications, smoking status and smoke exposure before and during pregnancy, alcohol consumption before and during pregnancy, history of abortion, miscarriage, stillbirth, exercise frequency, and reported fish oil supplementation</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Chong 2015 ⁹⁵	Antenatal and Postpartum Depression N Total: 698	26- 28 wk	Log plasma AA:DHA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 1.05 95% CI(0.08, 13.44)	
	Antenatal and Postpartum Depression N Total: 698	26- 28 wk	Log plasma AA:DPA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 1.65 95% CI(0.12, 23.39)	
	Antenatal and Postpartum Depression N Total: 698	26- 28 wk	Log plasma AA:EPA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 1.38 95% CI(0.31, 6.18)	
	Antenatal and Postpartum Depression N Total: 698	26- 28 wk	Log plasma total omega-3 n-3 Measure: Maternal n-3 Units: ug/ml	All N Quantile: na N Cases: na	OR Estimate: 1.4 95% CI(0.29, 6.73)	
	Antenatal and Postpartum Depression N Total: 698	3 month postpartum	Log plasma AA:DHA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 0.74 95% CI(0.08, 6.69)	
	Antenatal and Postpartum Depression N Total: 698	3 month postpartum	Log plasma AA:DPA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 3.81 95% CI(0.39, 37.06)	
	Antenatal and Postpartum Depression N Total: 698	3 month postpartum	Log plasma AA:EPA ratio n-3 Measure: Maternal	All N Quantile: na N Cases: na	OR Estimate: 0.54 95% CI(0.16, 1.85)	
	Antenatal and Postpartum Depression N Total: 698	3 month postpartum	Log plasma total omega-4 n-3 Measure: Maternal n-3 Units: ug/ml	All N Quantile: na N Cases: na	OR Estimate: 1.48 95% CI(0.40, 5055)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Clausen, et al., 2001⁶⁸</p> <p>Study dates: 12/94-8/96</p> <p>Study design: Observational prospective</p> <p>Location: Norway</p> <p>Funding source / conflict: NR</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 3,771 Pregnant completers 3,133</p> <p>Pregnant age: 29.8 (4.5)</p> <p>Race of Mother: White European (100)</p>	<p>Inclusion Criteria: Caucasian women seen at Aker University Hospital for prenatal care and who agreed to undergo ultrasound at their first prenatal visit and who completed a FFQ</p> <p>Exclusion Criteria: Pregestational diabetes, abortion, twin or triplet pregnancies, patients who give birth at other hospitals, missing records, loss to follow-up</p>	<p>Adjustments: Age, smoking (yes or no), BMI (<=20, 20-25, 25-30, >30), systolic blood pressure before 20 weeks' gestation, and nullipara (yes or no)</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Clausen 2001 ⁶⁸	Preeclampsia N Total: 3133		n-3 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T1 <=0.9 N Cases: 39	OR	
	Preeclampsia N Total: 3133		n-3 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T2 0.9 - 1.6 N Cases: 35	OR Estimate: 1.4 95% CI(0.9, 2.3)	
	Preeclampsia N Total: 3133		n-3 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T3 >1.6 N Cases: 11	OR Estimate: 1.9 95% CI(0.9, 3.8)	
	Preeclampsia N Total: 3133		n-6 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T1 <=3.8 N Cases: 34	OR	
	Preeclampsia N Total: 3133		n-6 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T2 3.8 - 5.8 N Cases: 38	OR Estimate: 1.5 95% CI(0.9, 2.4)	
	Preeclampsia N Total: 3133		n-6 fatty acids n-3 Measure: FFQ n-3 Units: Energy %	T3 >5.8 N Cases: 13	OR Estimate: 2.2 95% CI(1.1, 4.4)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Dirix, et al., 2009 ⁸⁴ Study name: Maastricht Essential Fatty Acid Birth (MEFAB) Cohort Study dates: 1990-1997 Study design: Observational prospective Location: Netherlands Funding source / conflict: Government	Study Population: Healthy infants Healthy pregnant women Pregnant enrolled 1238 Pregnant completers 782 Infants enrolled 1238 Infants completers 782 Pregnant age: 29.0 26.2-31.7 Infant age: 40.1 wk 39.3-41.0 Race of Mother: White European (100)	Inclusion Criteria: gestational age of <16 weeks at study entry, singleton pregnancy, Caucasian race, diastolic blood pressure, 90 mmHg and the absence of any metabolic, cardiovascular, neurological or renal disorder at the time of recruitment Exclusion Criteria: excluded if infants were born preterm (gestational age < 37 weeks.), mothers had diabetes or developed pregnancy-induced hypertension, mothers had reported specific health problems in the past (e.g. diabetes mellitus, hypertension and heart, kidney, liver, gall bladder or thyroid gland disorders, one or both parents were non-Caucasians or values for any of the afore-mentioned exclusion criteria were missing. The mother – infant pairs were also excluded if fatty acid analyses were not reported or values were missing for birth weight, birth length and head circumference	Adjustments: Infant sex, gestational age, maternal height

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Dirix 2009 ⁸⁴	Birth weight N Total: 782		DHA @ 16 weeks n-3 Measure: Maternal plasma phospholipids n-3 Units: per %, w/w plasma phospholipids increase	N Quantile: 665 N Cases: NR	Coefficient Estimate: 52.1 95% CI(20.4, 83.8)	
	Birth weight N Total: 782		DHA @ 22 weeks n-3 Measure: Maternal plasma phospholipids n-3 Units: per %, w/w plasma phospholipids increase	N Quantile: 623 N Cases: NR	Coefficient Estimate: 31.18 95% CI(-4.301, 66.67)	
	Birth weight N Total: 782		DHA @ 32 weeks n-3 Measure: Maternal plasma phospholipids n-3 Units: per %, w/w plasma phospholipids increase	N Quantile: 644 N Cases: NR	Coefficient Estimate: 33.08 95% CI(-5.699, 71.86)	
	Birth weight N Total: 782		DHA @ delivery n-3 Measure: Maternal plasma phospholipids n-3 Units: per %, w/w plasma phospholipids increase	N Quantile: 608 N Cases: NR	Coefficient Estimate: 3.423 95% CI(-34.95, 41.8)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Drouillet, et al., 2009⁸⁰</p> <p>Study name: EDEN</p> <p>Study dates: February 2003 - September 2003</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Industry, Government, Multiple foundations and Societies</p> <p>Original, same study, or follow-up studies: Bernard, 2013⁸⁹</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 2002 Pregnant completers 1446</p> <p>Pregnant age: 29.2 (4.8)</p> <p>Race of Mother: NR</p>	<p>Inclusion Criteria: NR</p> <p>Exclusion Criteria: twin pregnancies, known diabetes before pregnancy, not being able to speak and read French, and planned moving away from the region</p>	<p>Adjustments: Centre, mother's age and height, smoking habits, parity, gestational age, newborn's sex, delay between birth and anthropometric measures, and BMI</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Drouillet 2009 ⁸⁰	Birth weight N Total: 1446		Increase of 1 SD of the intake consumed per d n-3 Measure: FFQ n-3 Units: n-3 FA (% PUFA intake)		Coefficient Estimate: 6.4 95% CI(NR)	P value: P=0.54

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Guxens, et al., 2011 ¹⁴⁴ Study name: INMA Study dates: Recruitment: July 2004 to July 2006 Follow-up: 14 months Study design: Observational prospective Location: Spain Funding source / conflict: Government, Multiple foundations and Societies Follow-up: 14 months Original, same study, or follow-up studies: Julvez, 2014 ¹⁴³	Study Population: Healthy infants Breast-feeding women Pregnant enrolled 657 Pregnant completers 622 Lactating enrolled 622 Lactating completers 582 Infants enrolled 622 Infants completers 582 (319 with LCPUFA data) Lactating enrolled 622 Lactating completers 582 Lactating age: 31.6 years (4.2 years) Infant age: 2 to 5 days postpartum Race of Mother: NR (NR)	Inclusion Criteria: age older than 16 years, intent to deliver at the reference hospital, singleton pregnancy Exclusion Criteria: no problems of communication, no assisted conception	Adjustments: Child's age, maternal and paternal: education, social class, attachment to child, mental health; maternal age, maternal alcohol use during pregnancy, use of gas stove, child age of food introduction

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Guxens, 2011 ¹⁴⁴	Cognitive Development N Total: 504	14 months	ALA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	High versus low levels dichotomized at median	Coefficient Estimate: 1.25 95% CI(-1.43, 3.93)	
	Cognitive Development N Total: 504	14 months	ALA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	Sample divided into only 2 groups - High vs Low levels	Coefficient Estimate: 1.25 95% CI(-1.43, 3.93)	
	Cognitive Development N Total: 504	14 months	DHA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	High versus low levels dichotomized at median	Coefficient Estimate: 0.58 95% CI(-2.08, 3.23)	
	Cognitive Development N Total: 504	14 months	DHA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	Sample divided into only 2 groups - High vs Low levels	Coefficient Estimate: 0.58 95% CI(-2.08, 3.23)	
	Cognitive Development N Total: 504	14 months	DPA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	High versus low levels dichotomized at median	Coefficient Estimate: 1.35 95% CI(-1.39, 4.08)	
	Cognitive Development N Total: 504	14 months	DPA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	Sample divided into only 2 groups - High vs Low levels	Coefficient Estimate: 1.35 95% CI(-1.39, 4.08)	
	Cognitive Development N Total: 504	14 months	EPA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	High versus low levels dichotomized at median	Coefficient Estimate: 0.63 95% CI(-2.18, 3.44)	
	Cognitive Development N Total: 504	14 months	EPA n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	Sample divided into only 2 groups - High vs Low levels	Coefficient Estimate: 0.63 95% CI(-2.18, 3.44)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Cognitive Development N Total: 504	14 months	Total n-3 n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	High versus low levels dichotomized at median	Coefficient Estimate: 1.76 95% CI(-0.88, 4.4)	
	Cognitive Development N Total: 504	14 months	Total n-3 n-3 Measure: Biomarker (colostrum) n-3 Units: weight (%)	Sample divided into only 2 groups - High vs Low levels	Coefficient Estimate: 1.76 95% CI(-0.88, 4.4)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Jordi Julvez, et al., 2014¹⁴³</p> <p>Study name: INMA</p> <p>Study dates: Enrollment conducted July 2004 to July 2006 Follow-up: 4 years</p> <p>Study design: Observational prospective</p> <p>Location: Spain</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p> <p>Follow-up: 4 years</p> <p>Original, same study, or follow-up studies: Guxens, 2011¹⁴⁴</p>	<p>Study Population: Breast-feeding women</p> <p>Pregnant enrolled 657 Pregnant completers 622</p> <p>Lactating enrolled 622 Lactating completers 582</p> <p>Infants enrolled 622 Infants completers 434</p> <p>Lactating enrolled 622 Lactating completers 582</p> <p>Lactating age: 31.6 years (4.2 years)</p> <p>Infant age: 2 to 5 days after birth</p> <p>Race of Mother: NR (NR)</p>	<p>Inclusion Criteria: age older than 16 years, intent to deliver at the reference hospital, singleton pregnancy</p> <p>Exclusion Criteria: no problems with communication, no assisted conception</p>	<p>Adjustments: Test conditions, child age & sex, parental age, parity, alcohol consumption and smoking during pregnancy, day care attendance, country of birth, maternal education, social class, mental health, attachment to child, and perceptive performance IQ at 14 months, maternal psych symptoms, verbal IQ at 4 years, pollutant exposure during pregnancy.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Julvez, 2013 ¹⁴³	Neuropsychological development N Total: 434	4 years	Total n-3 fatty acids n-3 Measure: Biomarker (colostrum) n-3 Units: NR	Tertile 2 vs. Tertile 1	Coefficient Estimate: 0.5 95% CI(-2.9, 3.9)	
	Neuropsychological development N Total: 434	4 years	Total n-3 fatty acids n-3 Measure: Biomarker (colostrum) n-3 Units: NR	Tertile 2 vs. Tertile 2	Coefficient Estimate: 1.8 95% CI(-1.7, 5.4)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Keim, et al., 2012¹⁶²</p> <p>Study name: Pregnancy, Infection and Nutrition Study</p> <p>Study dates: Recruitment between January 2001 and June 2005 Follow-up: 1 year</p> <p>Study design: Observational prospective</p> <p>Location: US</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 12 months</p>	<p>Study Population: Healthy infants Breast-feeding women</p> <p>Pregnant enrolled 1,169 Pregnant completers 689</p> <p>Infants enrolled 408 Infants completers 358</p> <p>Pregnant age: NR</p> <p>Infant age: 20 weeks gestation NA</p> <p>Race of Mother: White European (79.1%) Other race/ethnicity (21.0)</p>	<p>Inclusion Criteria: health women at less than 20 weeks of pregnancy</p> <p>Exclusion Criteria: pregnant with multiple fetuses, unable to communicate in English, under age 16 years, no access to a telephone, intention to go elsewhere for future care or delivery</p>	<p>Adjustments: Laboratory, infant sex, race, parity, maternal smoking, education, breastfeeding status and preterm status</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Keim, 2012 ¹⁶²	Mullen Scales of Early Learning - composite score N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0.9 95% CI(-1.5, 3.4)	
	Mullen Scales of Early Learning - composite score N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: -0.5 95% CI(-2.7, 1.7)	
	Mullen Scales of Early Learning - expressive language scale N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0.7 95% CI(-0.9, 2.3)	
	Mullen Scales of Early Learning - expressive language scale N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: -0.6 95% CI(-2.1, 0.8)	
	Mullen Scales of Early Learning - fine motor scale N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0 95% CI(-2, 2)	
	Mullen Scales of Early Learning - fine motor scale N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0.2 95% CI(-1.7, 2)	
	Mullen Scales of Early Learning - gross motor scale N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 1.2 95% CI(-1.1, 3.4)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Mullen Scales of Early Learning - gross motor scale N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 1.1 95% CI(-0.9, 3.1)	
	Mullen Scales of Early Learning - receptive language scale N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0.3 95% CI(-1.2, 1.7)	
	Mullen Scales of Early Learning - receptive language scale N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: -0.1 95% CI(-1.4, 1.2)	
	Mullen Scales of Early Learning - visual reception scale N Total: 266	12 months	AA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: 0.7 95% CI(-1.3, 2.8)	
	Mullen Scales of Early Learning - visual reception scale N Total: 266	12 months	DHA n-3 Measure: breast milk and formula n-3 Units: a change in fatty acid concentration of 1.0%.		Coefficient Estimate: -0.1 95% CI(-2, 1.8)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Klebanoff, et al., 2011⁴⁹</p> <p>Study dates: Jan 2005- Oct 2006</p> <p>Study design: Observational prospective</p> <p>Location: US</p> <p>Funding source / conflict: Government</p> <p>Original, same study, or follow-up studies: Harper, 2010²⁹</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 852 Pregnant completers 852</p> <p>Pregnant age: <1/month, 27.1 (5.6) 0.5-3 per week, 28.0 (5.6) >3 per week, 27.3 (5.7) (<1/month, 27.1 (5.6) 0.5-3 per week, 28.0 (5.6) >3 per week, 27.3 (5.7))</p> <p>Race of Mother: NR</p>	<p>Inclusion Criteria: at least one prior singleton preterm delivery between 20 0/7 and 36 6/7 weeks of gestation after spontaneous preterm labor or premature rupture of the membranes, and a current singleton pregnancy between 16 and 21 6/7 weeks of gestation</p> <p>Exclusion Criteria: evidence of a major fetal anomaly, intake of a fish oil supplement in excess of 500 mg per week at any time during the preceding month, allergy to fish, anticoagulation therapy, hypertension, White's classification D or higher diabetes, drug or alcohol abuse, seizure disorder, uncontrolled thyroid disease, clotting disorder, current or planned cerclage, or a plan to deliver either elsewhere or before 37 weeks of gestation</p>	<p>Adjustments: Study center, number of previous preterm births, gestation of earliest prior spontaneous preterm birth, receipt of omega-3 versus placebo supplement, smoking, age, education, body mass index and ethnicity</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Klebanoff 2011 ⁴⁹	Preterm birth N Total: 852		Erythrocyte DHA + EPA n-3 Measure: Maternal red blood cells n-3 Units: % of total fatty acids	Q1 <3.052 - N Cases: 176	OR	
	Preterm birth N Total: 852		Erythrocyte DHA + EPA n-3 Measure: Maternal red blood cells n-3 Units: % of total fatty acids	Q2 3.052 - 3.719 N Cases: 175	OR Estimate: 0.59 95% CI(0.37, 0.94)	
	Preterm birth N Total: 852		Erythrocyte DHA + EPA n-3 Measure: Maternal red blood cells n-3 Units: % of total fatty acids	Q3 3.723 - 4.426 N Cases: 175	OR Estimate: 0.84 95% CI(0.53, 1.32)	
	Preterm birth N Total: 852		Erythrocyte DHA + EPA n-3 Measure: Maternal red blood cells n-3 Units: % of total fatty acids	Q4 >4.426 N Cases: 175	OR Estimate: 0.71 95% CI(0.45, 1.15)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Leung, et al., 2013⁹⁴</p> <p>Study name: Alberta Pregnancy Outcomes and Nutrition (APrON) study</p> <p>Study dates: %n Study design: Observational prospective</p> <p>Location: Canada</p> <p>Funding source / conflict: NR</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 600 Pregnant withdrawals 125 Pregnant completers 475</p> <p>Pregnant age: 31.2 not depressed 31.6 depressed (4.16 not depressed 4.7 depressed) not reported</p> <p>Race of Mother: White European (87%) Other race/ethnicity (13%)</p>	<p>Inclusion Criteria: at least 16 years old with gestational age =27 weeks. Women must be in the first (T1) or second (T2) trimester</p> <p>Exclusion Criteria: Any woman who was 28 weeks or beyond, Non-English speakers, known drug and alcohol abusers, and those planning to move out of the region within 6 months</p>	<p>Adjustments: Born in Canada, prenatal and postnatal social support, prenatal EPDS, selenium</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Leung 2013 ⁹⁴	PPD N Total: 475		Biomarkers	N Cases: 59	OR Estimate: 1 95% CI(0.99, 1)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Lim, et al., 2015 ⁷¹ Study dates: 2009-2012 Study design: Observational prospective Location: NR Funding source / conflict: Industry, Government	Study Population: Healthy pregnant women Pregnant enrolled 1162 Pregnant completers 751 Infants completers Pregnant age: 1st tertile 29.9 2nd tertile 30.0 3rd tertile 31.7 _ (1st tertile 5. 2 2nd tertile 5.2, 3rd tertile 4.8) Race of Mother: Asian (100)	Inclusion Criteria: Healthy women in early pregnancy at one of 3 tertiary care hospitals in Singapore Exclusion Criteria: receiving chemotherapy, taking psychotropic drugs, or having type 1 diabetes	Adjustments: Adjusted for age, ethnicity, education, exercise, alcohol intake, smoking status, BMI, and height at the 26th to the 28th week of gestation, gestational diabetes, and heart rate, fish oil supplementation

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Lim 2015 ⁷¹	Gestational hypertension N Total: 751	26-28 weeks	AA n-3 Measure: Biomarker (maternal plasma) n-3 Units: 1% increase in % total FA	All N Quantile: NR N Cases: 28	OR Estimate: 1.07 95% CI(0.95, 1.22)	
	Gestational hypertension N Total: 751	26-28 weeks	Total n-3 PUFAs n-3 Measure: Biomarker (maternal plasma) n-3 Units: 1% increase in % total FA	All N Quantile: NR N Cases: 28	OR Estimate: 0.76 95% CI(0.60, 0.97)	
	Gestational hypertension N Total: 751	26-28 weeks	n-3 LCPUFA n-3 Measure: Biomarker (maternal plasma) n-3 Units: 1% increase in % total FA	All N Quantile: NR N Cases: 28	OR Estimate: 0.77 95% CI(0.60, 0.98)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Lumia, et al., 2011¹⁸⁸</p> <p>Study name: Finnish Type 1 Diabetes Prediction and Prevention Nutrition Study</p> <p>Study dates: 1997-2004</p> <p>Study design: NR</p> <p>Location: Finland</p> <p>Funding source / conflict: Industry, Government, Multiple foundations and Societies, None</p> <p>Follow-up: 5 years</p>	<p>Study Population: NR</p> <p>Infants enrolled 2908 Infants completers 2679</p> <p>Pregnant age: 14.8% <25 years at birth 35.4% 25-29 years 30.4% 30-34 years 19.5% =35 years</p> <p>Race of Mother: White European (100%)</p>	<p>Inclusion Criteria: infants at three university hospitals in Finland (Turku, Tampere and Oulu) whose cord blood was screened for HLA-conferred genetic susceptibility to type 1 diabetes (HLA-DQB1) and were found to have high or moderate genetic risk of type 1 diabetes</p> <p>Exclusion Criteria: Severe congenital malformations or diseases, parents of non-Caucasian origin or parents who did not have a working knowledge of Finnish, Swedish or English</p>	<p>Adjustments: Maternal age, mode of delivery, duration of gestation, number of earlier deliveries, birth weight, sex of the child, area of birth, maternal smoking during pregnancy, parental asthma or allergic rhinitis, maternal vocational education, pets at home, farming, contact with cow stable during the first year of life and the duration of total breastfeeding</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Lumia 2011 ¹⁸⁸	Asthma N Total: 2679	5 years	AA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <0.06 N Quantile: NR N Cases: NR	RR Estimate: 0.52 95% CI(0.32, 0.84)	P value: 0.025
	Asthma N Total: 2679	5 years	AA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 0.06- 0.11 N Quantile: NR N Cases: NR	RR	
	Asthma N Total: 2679	5 years	AA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >0.11- N Quantile: NR N Cases: NR	RR Estimate: 0.77 95% CI(0.51, 1.17)	
	Asthma N Total: 2679	5 years	ALA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <1.83 N Quantile: NR N Cases: NR	RR Estimate: 1.7 95% CI(1.14, 2.53)	P value: 0.022
	Asthma N Total: 2679	5 years	ALA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 1.83- 3.18 N Quantile: NR N Cases: NR	RR	
	Asthma N Total: 2679	5 years	ALA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >3.18- N Quantile: NR N Cases: NR	RR Estimate: 1.06 95% CI(0.68, 1.65)	
	Asthma N Total: 2679	5 years	DHA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <0.10 N Quantile: NR N Cases: NR	RR Estimate: 0.8 95% CI(0.52, 1.23)	P value: 0.467
	Asthma N Total: 2679	5 years	DHA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 0.1- 0.32 N Quantile: NR N Cases: NR	RR	
	Asthma N Total: 2679	5 years	DHA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >0.32- N Quantile: NR N Cases: NR	RR Estimate: 0.83 95% CI(0.53, 1.29)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Asthma N Total: 2679		5 years	EPA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <0.04 N Quantile: NR N Cases: NR	RR Estimate: 1.09 95% CI(0.72, 1.65)	P value: 0.604
Asthma N Total: 2679		5 years	EPA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 0.04- 1.13 N Quantile: NR N Cases: NR	RR	
Asthma N Total: 2679		5 years	EPA n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >1.13- N Quantile: NR N Cases: NR	RR Estimate: 0.84 95% CI(0.54, 1.31)	
Asthma N Total: 2679		5 years	n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <2.24 N Quantile: NR N Cases: NR	RR Estimate: 1.66 95% CI(1.11, 2.48)	P value: 0.036
Asthma N Total: 2679		5 years	n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 2.24- 3.84 N Quantile: NR N Cases: NR	RR	
Asthma N Total: 2679		5 years	n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >3.84- N Quantile: NR N Cases: NR	RR Estimate: 1.09 95% CI(0.7, 1.7)	
Asthma N Total: 2679		5 years	n-6/n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q1 - <3.07 N Quantile: NR N Cases: NR	RR Estimate: 0.95 95% CI(0.62, 1.46)	P value: 0.835
Asthma N Total: 2679		5 years	n-6/n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q2,Q3 3.07- 3.82 N Quantile: NR N Cases: NR	RR	
Asthma N Total: 2679		5 years	n-6/n-3 PUFAs n-3 Measure: Maternal FFQ n-3 Units: g/d	Q4 >3.82- N Quantile: NR N Cases: NR	RR Estimate: 1.1 95% CI(0.72, 1.68)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Lyall, et al., 2013 ¹⁷¹ Study name: Nurses Health Study Study dates: Births 1991 to 2007 Study design: NR Location: US Funding source / conflict: Government	Study Population: Healthy pregnant women Pregnant enrolled 18,045 Pregnant completers 5,884 Pregnant age: Q1 34.7y Q4 33.7 y NR Infant age: birth Race of Mother: White European (Q1: 96%; Q4: 98%) Other race/ethnicity (Q1 4%; Q4 2%)	Inclusion Criteria: female nurses who were 25–42 years of age in 1989, with index births between 1991 (the year of first collection of dietary information) and 2007; women reported a child with ASD either in 2005 or 2009 not both, if 1) the reason for non-reporting on the other questionnaire was on participation in that questionnaire year; 2) the nurse confirmed the diagnosis in a previous substudy; or 3) for women reporting on the 2009 questionnaire only, the child was born after 2000 (in which case, the child might have been too young for report of diagnosis by the 2005 questionnaire mailing) Exclusion Criteria: Women reporting competing diagnoses (fragile X syndrome, Rett Syndrome, tuberous sclerosis, Down syndrome, trisomy 18; in a previous sub-study were not included.. women without food frequency questionnaire data or without autism diagnosis info on child	Adjustments: Adjusted for total energy intake, maternal age, child's year of birth, income level, race, body mass index, and pre-pregnancy smoking status. Removal of adjustment for smoking did not affect results. Additional adjustment for child birth order, maternal physical activity level, spouse's education level, or multivitamin use, or for trans-fat in PUFA model, did not materially alter estimates

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Lyall, 2013 ¹⁷¹	Autism Spectrum Disorders N Total: 17728		Total LCPUFA n-3 Measure: FFQ	Q1 7.8	RR	P value: P<0.008
	Autism Spectrum Disorders N Total: 17728		Total LCPUFA n-3 Measure: FFQ	Q2 9.5	RR Estimate: 0.97 95% CI(0.73, 1.3)	
	Autism Spectrum Disorders N Total: 17728		Total LCPUFA n-3 Measure: FFQ	Q3 11	RR Estimate: 0.82 95% CI(0.82, 1.11)	
	Autism Spectrum Disorders N Total: 17728		Total LCPUFA n-3 Measure: FFQ	Q4 13.4	RR Estimate: 0.67 95% CI(0.49, 0.92)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Miyake, et al., 2009 ¹⁸² Study name: Osaka maternal and child health study Study dates: 2002-2003 Study design: Observational prospective Location: Japan Funding source / conflict: Government, None	Study Population: Healthy infants Pregnant enrolled 1,002 Pregnant completers 763 Infants enrolled 1,002 Infants completers 763 Pregnant age: 30.0 (4.0) Race of Mother: NR (100)	Inclusion Criteria: pregnant women living in Neyagawa City, Osaka Prefecture or the surrounding cities Exclusion Criteria: Not reported	Adjustments: Maternal age, gestation at baseline, residential municipality, family income, maternal and paternal education, maternal and paternal history of asthma, atopic eczema and allergic rhinitis, maternal intake of vitamins D and E during pregnancy, changes in maternal diet in the previous 1 month, season when data at baseline were collected, maternal smoking during pregnancy, baby's older siblings, baby's sex, baby's birth weight, household smoking in the same room as the infant, breastfeeding duration and time of delivery before the third survey

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Miyake 2009 ¹⁸²	Eczema N Total: 763	16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.3 N Quantile: NR N Cases: 35	OR	P value: 0.06
	Eczema N Total: 763	16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 1.6 N Quantile: NR N Cases: 33	OR Estimate: 1.28 95% CI(0.71, 2.29)	
	Eczema N Total: 763	16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 1.9 N Quantile: NR N Cases: 35	OR Estimate: 1.69 95% CI(0.91, 3.13)	
	Eczema N Total: 763	16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.3 N Quantile: NR N Cases: 39	OR Estimate: 1.79 95% CI(0.93, 3.5)	
	Eczema N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.15 N Quantile: NR N Cases: 40	OR	P value: 0.57
	Eczema N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.24 N Quantile: NR N Cases: 40	OR Estimate: 1.5 95% CI(0.76, 3.02)	
	Eczema N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.32 N Quantile: NR N Cases: 32	OR Estimate: 1.11 95% CI(0.49, 2.54)	
	Eczema N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.46 N Quantile: NR N Cases: 30	OR Estimate: 0.86 95% CI(0.33, 2.28)	
	Eczema N Total: 763	16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.08 N Quantile: NR N Cases: 39	OR	P value: 0.95

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Eczema N Total: 763		16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.13 N Quantile: NR N Cases: 36	OR Estimate: 0.99 95% CI(0.51, 1.89)	
Eczema N Total: 763		16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.18 N Quantile: NR N Cases: 33	OR Estimate: 1.12 95% CI(0.52, 2.45)	
Eczema N Total: 763		16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.28 N Quantile: NR N Cases: 34	OR Estimate: 0.98 95% CI(0.39, 2.5)	
Eczema N Total: 763		16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.7 N Quantile: NR N Cases: 35	OR	P value: 0.2
Eczema N Total: 763		16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 2.2 N Quantile: NR N Cases: 38	OR Estimate: 1.72 95% CI(0.95, 3.13)	
Eczema N Total: 763		16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 2.5 N Quantile: NR N Cases: 33	OR Estimate: 1.63 95% CI(0.83, 3.22)	
Eczema N Total: 763		16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 3 N Quantile: NR N Cases: 36	OR Estimate: 1.74 95% CI(0.82, 3.73)	
Eczema N Total: 763		16-24 months	n-3/n-6 n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.17 N Quantile: NR N Cases: 31	OR	P value: 0.18
Eczema N Total: 763		16-24 months	n-3/n-7 n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.19 N Quantile: NR N Cases: 33	OR Estimate: 1.24 95% CI(0.68, 2.28)	
Eczema N Total: 763		16-24 months	n-3/n-8 n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.21 N Quantile: NR N Cases: 46	OR Estimate: 2.13 95% CI(1.17, 3.96)	
Eczema N Total: 763		16-24 months	n-3/n-9 n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.24 N Quantile: NR N Cases: 32	OR Estimate: 1.32 95% CI(0.65, 2.71)	
Wheeze N Total: 763		16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.3 N Quantile: NR N Cases: 53	OR	P value: 0.08
Wheeze N Total: 763		16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 1.6 N Quantile: NR N Cases: 38	OR Estimate: 0.63 95% CI(0.37, 1.07)	
Wheeze N Total: 763		16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 1.9 N Quantile: NR N Cases: 45	OR Estimate: 0.78 95% CI(0.45, 1.35)	
Wheeze N Total: 763		16-24 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.3 N Quantile: NR N Cases: 33	OR	
Wheeze N Total: 763		16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.15 N Quantile: NR N Cases: 55	OR	P value: 0.14

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheeze N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.24 N Quantile: NR N Cases: 29	OR Estimate: 0.41 95% CI(0.2, 0.81)	
	Wheeze N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.32 N Quantile: NR N Cases: 50	OR Estimate: 0.72 95% CI(0.33, 1.57)	
	Wheeze N Total: 763	16-24 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.46 N Quantile: NR N Cases: 35	OR	
	Wheeze N Total: 763	16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.08 N Quantile: NR N Cases: 48	OR	P value: 0.58
	Wheeze N Total: 763	16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.13 N Quantile: NR N Cases: 39	OR Estimate: 0.77 95% CI(0.42, 1.41)	
	Wheeze N Total: 763	16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.18 N Quantile: NR N Cases: 38	OR Estimate: 0.76 95% CI(0.37, 1.58)	
	Wheeze N Total: 763	16-24 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.28 N Quantile: NR N Cases: 44	OR Estimate: 0.76 95% CI(0.33, 1.8)	
	Wheeze N Total: 763	16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.7 N Quantile: NR N Cases: 53	OR	P value: 0.13
	Wheeze N Total: 763	16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 2.2 N Quantile: NR N Cases: 38	OR Estimate: 0.57 95% CI(0.33, 0.99)	
	Wheeze N Total: 763	16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 2.5 N Quantile: NR N Cases: 42	OR Estimate: 0.66 95% CI(0.36, 1.22)	
	Wheeze N Total: 763	16-24 months	n-3 PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 3 N Quantile: NR N Cases: 36	OR Estimate: 0.53 95% CI(0.26, 1.08)	
	Wheeze N Total: 763	16-24 months	n-3/n-6 n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.17 N Quantile: NR N Cases: 46	OR	P value: 0.38
	Wheeze N Total: 763	16-24 months	n-3/n-7 n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.19 N Quantile: NR N Cases: 44	OR Estimate: 0.88 95% CI(0.52, 1.51)	
	Wheeze N Total: 763	16-24 months	n-3/n-8 n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.21 N Quantile: NR N Cases: 37	OR Estimate: 0.69 95% CI(0.39, 1.23)	
	Wheeze N Total: 763	16-24 months	n-3/n-9 n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.24 N Quantile: NR N Cases: 42	OR Estimate: 0.81 95% CI(0.42, 1.55)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Miyake, et al., 2013¹⁸³</p> <p>Study name: Kyushu Okinawa Maternal and Child Health Study</p> <p>Study dates: 2007-2010</p> <p>Study design: Observational prospective</p> <p>Location: Japan</p> <p>Funding source / conflict: Industry, Government, Multiple foundations and Societies</p> <p>Follow-up: 23-29 months</p>	<p>Study Population: Healthy infants</p> <p>Pregnant enrolled 1757 Pregnant completers 1354</p> <p>Infants enrolled 1757 Infants completers 1354</p> <p>Pregnant age: 31.5 (4.1)</p> <p>Race of Mother: NR (100)</p>	<p>Inclusion Criteria: Women living in one of 7 prefectures on Kyushu Island who became pregnant from 2007-2008</p> <p>Exclusion Criteria: Failure to complete the study surveys</p>	<p>Adjustments: Maternal age, gestation at baseline, residential municipality, family income, maternal and paternal education, maternal and paternal history of asthma, atopic eczema and allergic rhinitis, maternal intake of vitamins D and E during pregnancy, changes in maternal diet in the previous 1 month, season when data at baseline were collected, maternal smoking during pregnancy, baby's older siblings, baby's sex, baby's birth weight, household smoking in the same room as the infant, breastfeeding duration and time of delivery before the third survey</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Miyake 2013 ¹⁸³	Eczema N Total: 763	23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.09 N Quantile: NR N Cases: 56	OR	
	Eczema N Total: 763	23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.12 N Quantile: NR N Cases: 61	OR Estimate: 1.08 95% CI(0.72, 1.63)	
	Eczema N Total: 763	23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.14 N Quantile: NR N Cases: 61	OR Estimate: 1.07 95% CI(0.71, 1.6)	
	Eczema N Total: 763	23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.18 N Quantile: NR N Cases: 51	OR Estimate: 0.87 95% CI(0.57, 1.33)	
	Eczema N Total: 763	23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.2 N Quantile: NR N Cases: 61	OR	
	Eczema N Total: 763	23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 1.5 N Quantile: NR N Cases: 52	OR Estimate: 0.82 95% CI(0.54, 1.24)	
	Eczema N Total: 763	23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 1.8 N Quantile: NR N Cases: 61	OR Estimate: 0.97 95% CI(0.65, 1.45)	
	Eczema N Total: 763	23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.2 N Quantile: NR N Cases: 55	OR Estimate: 0.86 95% CI(0.57, 1.29)	
	Eczema N Total: 763	23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.15 N Quantile: NR N Cases: 45	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Eczema N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.23 N Quantile: NR N Cases: 64	OR Estimate: 1.51 95% CI(0.99, 2.32)	
Eczema N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.3 N Quantile: NR N Cases: 58	OR Estimate: 1.35 95% CI(0.88, 2.08)	
Eczema N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.45 N Quantile: NR N Cases: 62	OR Estimate: 1.45 95% CI(0.95, 2.24)	
Eczema N Total: 763		23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.22 N Quantile: NR N Cases: 48	OR	
Eczema N Total: 763		23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.35 N Quantile: NR N Cases: 62	OR Estimate: 1.35 95% CI(0.89, 2.06)	
Eczema N Total: 763		23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.47 N Quantile: NR N Cases: 55	OR Estimate: 1.18 95% CI(0.77, 1.82)	
Eczema N Total: 763		23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.73 N Quantile: NR N Cases: 64	OR Estimate: 1.42 95% CI(0.93, 2.17)	
Eczema N Total: 763		23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.07 N Quantile: NR N Cases: 54	OR	
Eczema N Total: 763		23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.13 N Quantile: NR N Cases: 56	OR Estimate: 1.03 95% CI(0.68, 1.57)	
Eczema N Total: 763		23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.17 N Quantile: NR N Cases: 55	OR	
Eczema N Total: 763		23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.28 N Quantile: NR N Cases: 64	OR Estimate: 1.21 95% CI(0.8, 1.83)	
Eczema N Total: 763		23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.6 N Quantile: NR N Cases: 56	OR	
Eczema N Total: 763		23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 2.1 N Quantile: NR N Cases: 53	OR Estimate: 0.93 95% CI(0.61, 1.41)	
Eczema N Total: 763		23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 2.4 N Quantile: NR N Cases: 68	OR Estimate: 1.21 95% CI(0.81, 1.81)	
Eczema N Total: 763		23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.9 N Quantile: NR N Cases: 52	OR Estimate: 0.89 95% CI(0.58, 1.35)	
Eczema N Total: 763		23-29 months	n-3:n-6 n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.17 N Quantile: NR N Cases: 50	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Eczema N Total: 763		23-29 months	n-3:n-7 n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.19 N Quantile: NR N Cases: 59	OR Estimate: 1.21 95% CI(0.8, 1.85)	
Eczema N Total: 763		23-29 months	n-3:n-8 n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.21 N Quantile: NR N Cases: 57	OR Estimate: 1.14 95% CI(0.75, 1.76)	
Eczema N Total: 763		23-29 months	n-3:n-9 n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.25 N Quantile: NR N Cases: 63	OR Estimate: 1.28 95% CI(0.84, 1.95)	
Wheeze N Total: 763		23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.09 N Quantile: NR N Cases: 91	OR	
Wheeze N Total: 763		23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.12 N Quantile: NR N Cases: 99	OR Estimate: 1.12 95% CI(0.79, 1.59)	
Wheeze N Total: 763		23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.14 N Quantile: NR N Cases: 92	OR Estimate: 1.04 95% CI(0.74, 1.48)	
Wheeze N Total: 763		23-29 months	AA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.18 N Quantile: NR N Cases: 91	OR Estimate: 0.95 95% CI(0.66, 1.34)	
Wheeze N Total: 763		23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.2 N Quantile: NR N Cases: 91	OR	
Wheeze N Total: 763		23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 1.5 N Quantile: NR N Cases: 92	OR Estimate: 1.02 95% CI(0.72, 1.44)	
Wheeze N Total: 763		23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 1.8 N Quantile: NR N Cases: 97	OR Estimate: 1.06 95% CI(0.75, 1.5)	
Wheeze N Total: 763		23-29 months	ALA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.2 N Quantile: NR N Cases: 93	OR Estimate: 0.96 95% CI(0.68, 1.36)	
Wheeze N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.15 N Quantile: NR N Cases: 98	OR	
Wheeze N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.23 N Quantile: NR N Cases: 107	OR Estimate: 1.14 95% CI(0.81, 1.6)	
Wheeze N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.3 N Quantile: NR N Cases: 86	OR Estimate: 0.82 95% CI(0.58, 1.17)	
Wheeze N Total: 763		23-29 months	DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.45 N Quantile: NR N Cases: 82	OR Estimate: 0.77 95% CI(0.54, 1.1)	
Wheeze N Total: 763		23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.22 N Quantile: NR N Cases: 100	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheeze N Total: 763	23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.35 N Quantile: NR N Cases: 103	OR Estimate: 1.07 95% CI(0.76, 1.51)	
	Wheeze N Total: 763	23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.47 N Quantile: NR N Cases: 93	OR Estimate: 0.87 95% CI(0.62, 1.25)	
	Wheeze N Total: 763	23-29 months	EPA+DHA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.73 N Quantile: NR N Cases: 77	OR Estimate: 0.7 95% CI(0.49, 1.003)	
	Wheeze N Total: 763	23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.07 N Quantile: NR N Cases: 100	OR	
	Wheeze N Total: 763	23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.13 N Quantile: NR N Cases: 109	OR Estimate: 1.19 95% CI(0.84, 1.67)	
	Wheeze N Total: 763	23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.17 N Quantile: NR N Cases: 86	OR Estimate: 0.79 95% CI(0.55, 1.13)	
	Wheeze N Total: 763	23-29 months	EPA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.28 N Quantile: NR N Cases: 78	OR Estimate: 0.73 95% CI(0.5, 1.04)	
	Wheeze N Total: 763	23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q1 1.6 N Quantile: NR N Cases: 95	OR	
	Wheeze N Total: 763	23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q2 2.1 N Quantile: NR N Cases: 99	OR Estimate: 1.05 95% CI(0.75, 1.49)	
	Wheeze N Total: 763	23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q3 2.4 N Quantile: NR N Cases: 96	OR Estimate: 0.97 95% CI(0.69, 1.38)	
	Wheeze N Total: 763	23-29 months	n-3-PUFA n-3 Measure: FFQ n-3 Units: median, g/d	Q4 2.9 N Quantile: NR N Cases: 83	OR Estimate: 0.79 95% CI(0.55, 1.12)	
	Wheeze N Total: 763	23-29 months	n-3:n-6 n-3 Measure: FFQ n-3 Units: median, g/d	Q1 0.17 N Quantile: NR N Cases: 90	OR	
	Wheeze N Total: 763	23-29 months	n-3:n-7 n-3 Measure: FFQ n-3 Units: median, g/d	Q2 0.19 N Quantile: NR N Cases: 104	OR Estimate: 1.24 95% CI(0.88, 1.75)	
	Wheeze N Total: 763	23-29 months	n-3:n-8 n-3 Measure: FFQ n-3 Units: median, g/d	Q3 0.21 N Quantile: NR N Cases: 97	OR Estimate: 1.08 95% CI(0.76, 1.54)	
	Wheeze N Total: 763	23-29 months	n-3:n-9 n-3 Measure: FFQ n-3 Units: median, g/d	Q4 0.25 N Quantile: NR N Cases: 82	OR Estimate: 0.85 95% CI(0.59, 1.22)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Mohanty, et al., 2015⁸⁵</p> <p>Study dates: 1996-2008</p> <p>Study design: Observational prospective</p> <p>Location: US</p> <p>Funding source / conflict: Government</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant completers 534</p> <p>Race of Mother: White European (88)</p>	<p>Inclusion Criteria: initiated prenatal care at or before 20 weeks gestation, were aged = 18 years, able to speak and read English, planned to carry the pregnancy to term, and to deliver at either of the two hospitals</p> <p>Exclusion Criteria: multi-fetal pregnancies, implausible total energy intake of <500 or >3500 kcal/day, pregnancies complicated by fetal demise (after 20 weeks of gestation), missing labor and delivery information, missing information on fetal growth indices, missing seafood intake information</p>	<p>Adjustments: Adjusted for maternal age (years), non-Hispanic white race, post high-school education, unmarried marital status, pre-pregnancy body mass index (indicator variables: 18.5-24.9, 25-29.9, =30 kg/m2), total energy (kcal/day), current recreational physical activity, current smoking, current alcohol intake, nulliparity, intake of red/processed meats (servings/day), male infant sex.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Mohanty 2015 ⁸⁵	Birth weight N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q1 2.28-4.49 N Quantile: 133	Mean difference	
	Birth weight N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q2 4.49-5.25 N Quantile: 134	Mean difference Estimate: -59 95% CI(-207.5, 89.6)	
	Birth weight N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q3 5.26-6.07 N Quantile: 133	Mean difference Estimate: 49.6 95% CI(-100.9, 200.1)	
	Birth weight N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q4 6.07-9.55 N Quantile: 134	Mean difference Estimate: -39.4 95% CI(-194.5, 115.7)	
	Head circumference N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q1 2.28-4.49 N Quantile: 133	Mean difference	
	Head circumference N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q2 4.49-5.25 N Quantile: 134	Mean difference Estimate: 0.3 95% CI(-0.3, 0.9)	
	Head circumference N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q3 5.26-6.07 N Quantile: 133	Mean difference Estimate: 0.5 95% CI(-0.1, 1.1)	
	Head circumference N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q4 6.07-9.55 N Quantile: 134	Mean difference Estimate: 0.2 95% CI(-0.4, 0.9)	
	Length N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q1 2.28-4.49 N Quantile: 133	Mean difference	
	Length N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q2 4.49-5.25 N Quantile: 134	Mean difference Estimate: -0.1 95% CI(-0.9, 0.6)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Length N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q3 5.26-6.07 N Quantile: 133	Mean difference Estimate: -0.1 95% CI(-0.9, 0.6)	
	Length N Total: 534		Erythrocyte DHA + EPA n-3 Measure: Maternal n-3 Units: % total fatty acids	Q4 6.07-9.55 N Quantile: 134	Mean difference Estimate: 0 95% CI(-0.9, 0.8)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Molto-Puigmarti, et al., 2014⁴⁸</p> <p>Study name: KOALA Birth Cohort Study</p> <p>Study dates: 2000-2002</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Multiple foundations and Societies</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 2669 Pregnant completers 1516</p> <p>Infants enrolled 2669 Infants completers 1515</p> <p>Pregnant age: years (.7yrs)</p> <p>Race of Mother: NR (100)</p>	<p>Inclusion Criteria: nr, Described in Ref 37</p> <p>Exclusion Criteria: nr</p>	<p>Adjustments: Adjusted for child gender, study recruitment group, maternal education, parity, maternal smoking status during pregnancy, maternal alcohol use in pregnancy, and maternal age at delivery</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Molto-Puigmarti 2014 ⁴⁸	<p>Birth weight</p> <p>N Total: 2606</p> <p>Pregnancy duration</p> <p>N Total: 2606</p>		<p>DHA</p> <p>n-3 Measure: Maternal</p> <p>n-3 Units: mg/d</p> <p>DHA</p> <p>n-3 Measure: Maternal</p> <p>n-3 Units: mg/d</p>	<p>All</p> <p>N Quantile: na</p> <p>N Cases: na</p> <p>All</p> <p>N Quantile: na</p> <p>N Cases: na</p>	<p>Coefficient</p> <p>Estimate: 0.16</p> <p>95% CI(0.008, 0.313)</p> <p>Coefficient</p> <p>Estimate: 0.004</p> <p>95% CI(0.001, 0.007)</p>	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Morales, et al., 2012¹⁸⁴</p> <p>Study name: INfancia y Medio Ambiente (INMA) Project</p> <p>Study dates: 2004-2007</p> <p>Study design: Observational prospective</p> <p>Location: Spain</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 14 months</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 622 Pregnant completers 580</p> <p>Infants enrolled 622 Infants completers 580</p> <p>Mother age: 31.6 (4.2)</p> <p>Race of Mother: NR (100)</p>	<p>Inclusion Criteria: to be resident in the study area, to be at least 16 years old, to have a singleton pregnancy, to not have followed any programme of assisted reproduction, to wish to deliver in the reference hospital, and to have no communication problems</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: Child gender, maternal social class, siblings at birth, maternal smoking in pregnancy, and DDE levels in cord blood for wheezing outcome</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Morales 2012 ¹⁸⁴	Wheezing N Total: 197	6 &14 months	AA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.34 95% CI(0.44, 4.06)	
	Wheezing N Total: 197	6 &14 months	ALA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.57 95% CI(0.42, 5.84)	
	Wheezing N Total: 197	6 &14 months	All n-3 n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.08 95% CI(0.37, 3.18)	
	Wheezing N Total: 197	6 &14 months	DHA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.91 95% CI(0.31, 2.67)	
	Wheezing N Total: 197	6 &14 months	EPA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.56 95% CI(0.15, 2.08)	
	Wheezing N Total: 269	7-14 months	AA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.36 95% CI(0.69, 2.65)	
	Wheezing N Total: 269	7-14 months	ALA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.82 95% CI(0.4, 1.69)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheezing N Total: 269	7-14 months	All n-3 n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.72 95% CI(0.36, 1.44)	
	Wheezing N Total: 269	7-14 months	DHA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.94 95% CI(0.48, 1.86)	
	Wheezing N Total: 269	7-14 months	EPA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.58 95% CI(0.27, 1.24)	
	Wheezing N Total: 272	0-6 months	AA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.19 95% CI(0.51, 2.76)	
	Wheezing N Total: 272	0-6 months	ALA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.54 95% CI(0.62, 3.78)	
	Wheezing N Total: 272	0-6 months	All n-3 n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 1.35 95% CI(0.58, 3.13)	
	Wheezing N Total: 272	0-6 months	DHA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 0.91 95% CI(0.41, 2.03)	
	Wheezing N Total: 272	0-6 months	EPA n-3 Measure: Colostrum fatty acid concentration n-3 Units: weight-percentage (wt%, mg/100 mg) of total fatty acids	Highest vs. lowest tertile odds ratios N Quantile: NR	OR Estimate: 2.24 95% CI(0.76, 6.55)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Much, et al., 2013¹⁰¹</p> <p>Study name: INFAT</p> <p>Study dates: Recruitment: 2006-2009 Follow-up: 1 year</p> <p>Study design: Observational prospective</p> <p>Location: Germany</p> <p>Funding source / conflict: Industry, Government, Some authors employed by industry (companies that make the supplements)</p> <p>Follow-up: 1 year</p> <p>Original, same study, or follow-up studies: Hauner, 2012³⁷</p>	<p>Study Population: Healthy infants Breast-feeding women</p> <p>Pregnant enrolled 208</p> <p>Lactating enrolled 152 at 6 weeks/120 at 4 months</p> <p>Infants enrolled 56 at 4 months/31 at 12 months</p> <p>Lactating enrolled 152 at 6 weeks/120 at 4 months</p> <p>Pregnant age: Intervention: 31.9 Control: 31.6 (Intervention: 4.9 Control: 4.5)</p> <p>Race of Mother: NR (NR)</p>	<p>Inclusion Criteria: Gestational age =15th wk of gestation, between 18 and 43 y of age, pre-pregnancy BMI (in kg/m²) between 18 and 30, willingness to implement the dietary recommendations, sufficient German language skills, and written informed consent</p> <p>Exclusion Criteria: High-risk pregnancy (multiple pregnancy, rhesus incompatibility, hepatitis B infection, or parity >4); hypertension; chronic diseases (e.g., diabetes) or gastrointestinal disorders accompanied by maldigestion, malabsorption, or elevated energy and nutritional requirements (e.g., gluten enteropathy); known metabolic defects (e.g., phenylketonuria); psychiatric diseases; hyperemesis gravidarum; supplementation with n-3 LCPUFAs before randomization; and alcohol abuse and smoking</p>	<p>Adjustments: Gestational age, parity, infant sex, group, ponderal index at birth, breastfeeding status of infants at 6 wk, 4 mo, and 1 yr.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Much 2013 ¹⁰¹	BMI at 1 yr N Total: 117	1 y	DHA n-3 Measure: Breast milk at 4 mo postpartum n-3 Units: % wt		Coefficient Estimate: 0.86 95% CI(0.11, 1.62)	
	Length at 1 yr N Total: 117	1 y	EPA n-3 Measure: Breast milk at 4 mo postpartum n-3 Units: % wt		Coefficient Estimate: -12.43 95% CI(-20.36, -4.231)	
	Length at 4 mo N Total: 119	4 mo	EPA n-3 Measure: Breast milk at 4 mo postpartum n-3 Units: % wt		Coefficient Estimate: -7.85 95% CI(-14.94, -0.73)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Much, et al., 2013⁸³</p> <p>Study name: INFAT</p> <p>Study dates: >2009-<2013</p> <p>Study design: Observational prospective</p> <p>Location: Germany</p> <p>Funding source / conflict: Industry, Government, Some authors employed by industry (companies that make the supplements), Multiple foundations and Societies, None</p>	<p>Study Population: Healthy infants Breast-feeding women</p> <p>Pregnant enrolled 208</p> <p>Infants completers 187</p> <p>Race of Mother: NR (NR)</p>	<p>Inclusion Criteria: Healthy pregnant women at 14th week of gestation</p> <p>Exclusion Criteria: None reported</p>	<p>Adjustments: Pregnancy duration, group, parity, and sex</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Much 2013 ⁸³	Birth weight N Total: 187		DHA at 32 wks gestation n-3 Measure: Maternal red blood cells n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 24.38 95% CI(0.42, 48.33)	
	Birth weight N Total: 187		n-3 LCPUFA at 32 wks gestation n-3 Measure: Maternal red blood cells n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 20.38 95% CI(2.78, 37.99)	
Much 2013 ⁸³	BMI N Total: 169	12 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: -0.04 95% CI(-0.11, 0.04)	
	BMI N Total: 169	12 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: -0.02 95% CI(-0.08, 0.04)	
	BMI N Total: 172	4 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.04 95% CI(-0.04, 0.12)	
	BMI N Total: 172	4 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.03 95% CI(-0.03, 0.09)	
	BMI N Total: 177	6 wks	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.05 95% CI(-0.02, 0.12)	
	BMI N Total: 177	6 wks	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.04 95% CI(-0.01, 0.09)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	BMI N Total: 187	Birth	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.04 95% CI(-0.03, 0.1)	
	BMI N Total: 187	Birth	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.03 95% CI(-0.02, 0.08)	
	Head circumference N Total: 169	12 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.01 95% CI(-0.08, 0.22)	
	Head circumference N Total: 169	12 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.01 95% CI(-0.05, 0.08)	
	Head circumference N Total: 172	4 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.02 95% CI(-0.04, 0.09)	
	Head circumference N Total: 172	4 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.03 95% CI(-0.02, 0.08)	
	Head circumference N Total: 177	6 wks	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.02 95% CI(-0.04, 0.1)	
	Head circumference N Total: 177	6 wks	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.02 95% CI(-0.02, 0.07)	
	Head circumference N Total: 187	Birth	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.07 95% CI(0, 0.14)	
	Head circumference N Total: 187	Birth	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.06 95% CI(0.01, 0.12)	
	Length N Total: 169	12 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.07 95% CI(-0.08, 0.22)	
	Length N Total: 169	12 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.04 95% CI(-0.07, 0.15)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Length N Total: 172	4 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.03 95% CI(-0.09, 0.15)	
	Length N Total: 172	4 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.02 95% CI(-0.07, 0.11)	
	Length N Total: 177	6 wks	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.05 95% CI(-0.07, 0.18)	
	Length N Total: 177	6 wks	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.05 95% CI(-0.04, 0.15)	
	Length N Total: 187	Birth	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.12 95% CI(-0.01, 0.24)	
	Length N Total: 187	Birth	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 0.1 95% CI(0.01, 0.19)	
	Weight N Total: 169	12 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: -0.99 95% CI(-58.1, 56.12)	
	Weight N Total: 169	12 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 1.4 95% CI(-40.7, 43.5)	
	Weight N Total: 172	4 mo	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 19.72 95% CI(-19.25, 58.69)	
	Weight N Total: 172	4 mo	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 15.17 95% CI(-13.49, 43.84)	
	Weight N Total: 177	6 wks	DHA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 24.16 95% CI(-8.96, 57.29)	
	Weight N Total: 177	6 wks	n-3 LCPUFA n-3 Measure: Maternal red blood cells at 32 wks gestation n-3 Units: per unit increase in % of total FA		Coefficient Estimate: 21.53 95% CI(-2.81, 45.86)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Muthayya, et al., 2009⁷²</p> <p>Study dates: Jan 2002- Mar 2006</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Industry, Government</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 829 Pregnant completers 676</p> <p>Pregnant age: group 1, 23 group 2, 23 group 3, 23 total, 24 group 1, 21-26 group 2, 21-27 group 3, 23-29 total: 21-27</p> <p>Race of Mother: Asian (Indian, 100%)</p>	<p>Inclusion Criteria: pregnant women aged 17–40 years and at <20 weeks of gestation, registered for antenatal screening at the Department of Obstetrics and Gynecology at St John's Medical College Hospital,</p> <p>Exclusion Criteria: Women with multiple pregnancies, those with a clinical diagnosis of chronic illness such as diabetes mellitus, hypertension, heart disease and thyroid disease, those who tested positive for HbSAg/HIV/VDRL infection or who anticipated moving out of the city before delivery were excluded</p>	<p>Adjustments: Adjusted for maternal age, maternal education, parity, maternal weight/maternal weight gain per week and gestational age</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Muthayya 2009 ⁷²	Low birth weight N Total: 419		EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: mg/day	T1 0.28 N Cases: 133	AOR Estimate: 2.75 95% CI(1.26, 6.02)	
	Low birth weight N Total: 419		EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: mg/day	T2 3.03 N Cases: 148	AOR Estimate: 2.54 95% CI(1.17, 5.5)	
	Low birth weight N Total: 419		EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: mg/day	T3 9.53 N Cases: 138	AOR	
	Low birth weight N Total: 675		EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: mg/day	T1 0.24 N Cases: 225	AOR Estimate: 1.61 95% CI(0.92, 2.8)	
	Low birth weight N Total: 675		EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: mg/day	T2 2.1 N Cases: 224	AOR Estimate: 1.05 95% CI(0.59, 1.9)	
	Low birth weight N Total: 675		EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: mg/day	T3 9.37 N Cases: 226	AOR	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Newson, et al., 2004¹⁷⁶</p> <p>Study name: Avon Longitudinal Study of Parents and Children (ALSPAC)</p> <p>Study dates: Recruitment: April 1, 1991 to December 31, 1992 Follow-up: 42 months</p> <p>Study design: Observational prospective</p> <p>Location: UK</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p> <p>Follow-up: 42 months</p> <p>Original, same study, or follow-up studies: Golding et al., 2001 (ALSPAC)</p>	<p>Study Population: Healthy infants</p> <p>Pregnant enrolled 4136</p> <p>Infants enrolled 4202 Infants completers 1762</p> <p>Infant age: Prenatal</p> <p>Race of Mother: NR (100%)</p>	<p>Inclusion Criteria: Pregnant women with expected date of delivery between April 1, 1991, and December 31, 1992, and place of residence within the 3 Bristol-based health districts of the former county of Avon, United Kingdom</p> <p>Exclusion Criteria: NR for enrollment. Exclusion for analysis: multiple pregnancies or in small missing value categories for various confounders.</p>	<p>Adjustments: Child's sex, gestational age at birth, and birth weight, and for the mother's age, education level, housing tenure, parity, ethnicity, and smoking in pregnancy (for variable categories see Table E1 in the Journal's Online Repository at http://www.mosby.com/jaci), as well as maternal atopic disease (asthma, eczema, rhinoconjunctivitis), child's head circumference at birth (< 33 cm, 33-34.99 cm, 35-36.99 cm, 37+ cm, unknown), child's crown to heel length at birth (< 48 cm, 48-50.99 cm, 51-53.99 cm, 54+ cm, unknown), mother's body mass index (from pre-pregnancy self-reported weight and height; < 18.5 kg/m², 18.5-24.99 kg/m², 25-29.99 kg/m², 30+ kg/m², unknown), breast-feeding</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Newson 2004 ¹⁷⁶	Eczema N Total: 1238	30 months	18:3 n-3 ALA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1 95% CI(0.9, 1.11)	
	Eczema N Total: 1238	30 months	20:4 n-6 AA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.08 95% CI(0.93, 1.25)	
	Eczema N Total: 1238	30 months	20:5 n-3 EPA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.95 95% CI(0.86, 1.06)	
	Eczema N Total: 1238	30 months	22:6 n-3 DHA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1 95% CI(0.91, 1.1)	
	Eczema N Total: 1238	30 months	AA: EPA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.14 95% CI(1, 1.31)	
	Eczema N Total: 2945	30 months	18:3 n-3 ALA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1 95% CI(0.91, 1.09)	
	Eczema N Total: 2945	30 months	20:4 n-6 AA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.98 95% CI(0.88, 1.1)	
	Eczema N Total: 2945	30 months	20:5 n-3 EPA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.03 95% CI(0.94, 1.12)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Eczema N Total: 2945	30 months	22:6 n-3 DHA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.02 95% CI(0.94, 1.12)	
	Eczema N Total: 2945	30 months	AA: EPA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.95 95% CI(0.85, 1.05)	
	Wheezing N Total: 1191	42 months	18:3 n-3 ALA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.99 95% CI(0.85, 1.15)	
	Wheezing N Total: 1191	42 months	20:4 n-6 AA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.05 95% CI(0.86, 1.27)	
	Wheezing N Total: 1191	42 months	20:5 n-3 EPA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.01 95% CI(0.87, 1.17)	
	Wheezing N Total: 1191	42 months	22:6 n-3 DHA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.05 95% CI(0.93, 1.19)	
	Wheezing N Total: 1191	42 months	AA: EPA n-3 Measure: Cord blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.01 95% CI(0.85, 1.21)	
	Wheezing N Total: 2764	42 months	18:3 n-3 ALA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.03 95% CI(0.91, 1.16)	
	Wheezing N Total: 2764	42 months	20:4 n-6 AA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.02 95% CI(0.86, 1.2)	
	Wheezing N Total: 2764	42 months	20:5 n-3 EPA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.94 95% CI(0.84, 1.06)	
	Wheezing N Total: 2764	42 months	22:6 n-3 DHA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 0.99 95% CI(0.86, 1.13)	
	Wheezing N Total: 2764	42 months	AA: EPA n-3 Measure: Maternal blood n-3 Units: % of total RBC membrane phospholipid	All	Per doubling OR Estimate: 1.11 95% CI(0.95, 1.3)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Notenboom, et al., 2011¹⁷⁹</p> <p>Study name: KOALA Birth Cohort Study</p> <p>Study dates: Recruitment from October 2000 onwards and Follow-up: 6-7 years</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Industry, Government, Multiple foundations and Societies</p> <p>Follow-up: 3 - 84 months</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Infants enrolled 1275 Infants completers 1253 (samples for 815)</p> <p>Mother age: 32.6 (3.8)</p> <p>Race of Mother: White European (Dutch 96.3%)</p>	<p>Inclusion Criteria: Conventional participants: participation in ongoing study of pelvic girdle pain Alternative participants: frequented locations associated with organic diet and similar lifestyles Subsample: participants recruited from January 2002 onwards who consented to biosampling.</p> <p>Exclusion Criteria: Current multiple pregnancy n=9 Prematurity n=15 Perinatal infant death n=2 Down syndrome n=4 No response after birth n=51</p>	<p>Adjustments: Adjusted for recruitment group, maternal age, maternal ethnicity, maternal education level, maternal smoking during pregnancy, parental history of atopy, term of gestation, season of birth, gender, birth weight, mode of delivery, exposure to environmental tobacco, presence of older siblings and sibling atopy, breastfeeding, child day care, and pets at home</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Notenboom 2011 ¹⁷⁹	Allergic rhinoconjunctivitis N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: 192 N Cases: 13	OR	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: 199 N Cases: 14	OR Estimate: 1.04 95% CI(0.47, 2.27)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: 190 N Cases: 15	OR Estimate: 1.17 95% CI(0.54, 2.53)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: 199 N Cases: 12	OR Estimate: 0.87 95% CI(0.39, 1.197)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: 171 N Cases: 15	OR Estimate: 1.3 95% CI(0.59, 2.83)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: 176 N Cases: 14	OR	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: 189 N Cases: 16	OR Estimate: 1.07 95% CI(0.51, 2.26)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: 191 N Cases: 8	OR Estimate: 0.51 95% CI(0.21, 1.25)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: 205 N Cases: 15	OR Estimate: 0.92 95% CI(0.43, 2)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: 190 N Cases: 16	OR Estimate: 1.09 95% CI(0.51, 2.31)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: 195 N Cases: 8	OR	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: 194 N Cases: 14	OR Estimate: 1.81 95% CI(0.74, 4.41)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: 187 N Cases: 18	OR Estimate: 2.48 95% CI(1.05, 5.85)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: 183 N Cases: 12	OR Estimate: 1.62 95% CI(0.64, 4.06)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: 192 N Cases: 17	OR Estimate: 2.24 95% CI(0.94, 5.34)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: 195 N Cases: 19	OR	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: 185 N Cases: 10	OR Estimate: 0.53 95% CI(0.24, 1.17)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: 182 N Cases: 16	OR Estimate: 0.89 95% CI(0.44, 1.79)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: 191 N Cases: 16	OR Estimate: 0.85 95% CI(0.42, 1.71)	
	Allergic rhinoconjunctivitis N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: 198 N Cases: 8	OR Estimate: 0.4 95% CI(0.17, 0.92)	
	Allergic sensitization N Total: 768	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: 156 N Cases: 45	OR	
	Allergic sensitization N Total: 768	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: 159 N Cases: 42	OR Estimate: 0.81 95% CI(0.48, 1.34)	
	Allergic sensitization N Total: 768	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: 159 N Cases: 52	OR Estimate: 1.15 95% CI(0.7, 1.9)	
	Allergic sensitization N Total: 768	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: 153 N Cases: 41	OR Estimate: 0.86 95% CI(0.51, 1.46)	
	Allergic sensitization N Total: 768	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: 141 N Cases: 33	OR Estimate: 0.69 95% CI(0.39, 1.23)	
	Allergic sensitization N Total: 768	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: 152 N Cases: 44	OR	
	Allergic sensitization N Total: 768	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: 158 N Cases: 42	OR Estimate: 0.88 95% CI(0.53, 1.49)	
	Allergic sensitization N Total: 768	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: 152 N Cases: 41	OR Estimate: 0.96 95% CI(0.57, 1.62)	
	Allergic sensitization N Total: 768	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: 151 N Cases: 47	OR Estimate: 1.1 95% CI(0.65, 1.85)	
	Allergic sensitization N Total: 768	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: 155 N Cases: 39	OR Estimate: 0.82 95% CI(0.48, 1.4)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic sensitization N Total: 768	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: 143 N Cases: 40	OR	
	Allergic sensitization N Total: 768	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: 150 N Cases: 42	OR Estimate: 1.01 95% CI(0.59, 1.72)	
	Allergic sensitization N Total: 768	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: 155 N Cases: 44	OR Estimate: 1.03 95% CI(0.6, 1.76)	
	Allergic sensitization N Total: 768	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: 167 N Cases: 44	OR Estimate: 0.92 95% CI(0.53, 1.6)	
	Allergic sensitization N Total: 768	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: 153 N Cases: 43	OR Estimate: 1.04 95% CI(0.6, 1.8)	
	Allergic sensitization N Total: 768	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: 169 N Cases: 51	OR	
	Allergic sensitization N Total: 768	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: 146 N Cases: 39	OR Estimate: 0.79 95% CI(0.47, 1.33)	
	Allergic sensitization N Total: 768	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: 154 N Cases: 43	OR Estimate: 0.83 95% CI(0.5, 1.4)	
	Allergic sensitization N Total: 768	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: 159 N Cases: 38	OR Estimate: 0.73 95% CI(0.44, 1.24)	
	Allergic sensitization N Total: 768	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: 140 N Cases: 42	OR Estimate: 0.94 95% CI(0.56, 1.6)	
	Asthma N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: NR N Cases: NR	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Asthma N Total: 951		6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: NR N Cases: NR	OR Estimate: 1.69 95% CI(0.7, 4.1)	
Asthma N Total: 951		6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: NR N Cases: NR	OR Estimate: 1.29 95% CI(0.52, 3.2)	
Asthma N Total: 951		6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: NR N Cases: NR	OR Estimate: 0.82 95% CI(0.31, 2.15)	
Asthma N Total: 951		6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: NR N Cases: NR	OR Estimate: 1.7 95% CI(0.67, 4.33)	
Asthma N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: NR N Cases: NR	OR	
Asthma N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: NR N Cases: NR	OR Estimate: 1.14 95% CI(0.51, 2.55)	
Asthma N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: NR N Cases: NR	OR Estimate: 0.55 95% CI(0.21, 1.45)	
Asthma N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: NR N Cases: NR	OR Estimate: 1.08 95% CI(0.47, 2.49)	
Asthma N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: NR N Cases: NR	OR Estimate: 0.6 95% CI(0.23, 1.56)	
Asthma N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: NR N Cases: NR	OR	
Asthma N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.43, 2.89)	
Asthma N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: NR N Cases: NR	OR Estimate: 1.47 95% CI(0.56, 3.85)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Asthma N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: NR N Cases: NR	OR Estimate: 2.07 95% CI(0.82, 5.24)	
Asthma N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: NR N Cases: NR	OR Estimate: 1.87 95% CI(0.76, 4.63)	
Asthma N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: NR N Cases: NR	OR	
Asthma N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: NR N Cases: NR	OR Estimate: 1.85 95% CI(0.83, 4.12)	
Asthma N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.45, 2.71)	
Asthma N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: NR N Cases: NR	OR Estimate: 0.92 95% CI(0.37, 2.29)	
Asthma N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: NR N Cases: NR	OR Estimate: 0.85 95% CI(0.34, 2.16)	
Atopic dermatitis N Total: 807		24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: 161 N Cases: 20	OR	
Atopic dermatitis N Total: 807		24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: 166 N Cases: 23	OR Estimate: 1.15 95% CI(0.59, 2.28)	
Atopic dermatitis N Total: 807		24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: 166 N Cases: 24	OR Estimate: 1.24 95% CI(0.63, 2.44)	
Atopic dermatitis N Total: 807		24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: 162 N Cases: 26	OR Estimate: 1.35 95% CI(0.79, 2.65)	
Atopic dermatitis N Total: 807		24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: 152 N Cases: 18	OR Estimate: 0.94 95% CI(0.44, 1.98)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Atopic dermatitis N Total: 807	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: 159 N Cases: 18	OR	
	Atopic dermatitis N Total: 807	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: 163 N Cases: 18	OR Estimate: 0.89 95% CI(0.43, 1.85)	
	Atopic dermatitis N Total: 807	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: 156 N Cases: 24	OR Estimate: 1.63 95% CI(0.81, 3.27)	
	Atopic dermatitis N Total: 807	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: 161 N Cases: 31	OR Estimate: 2.17 95% CI(1.1, 4.27)	
	Atopic dermatitis N Total: 807	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: 168 N Cases: 20	OR Estimate: 1.16 95% CI(0.56, 2.39)	
	Atopic dermatitis N Total: 807	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: 155 N Cases: 23	OR	
	Atopic dermatitis N Total: 807	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: 154 N Cases: 21	OR Estimate: 0.94 95% CI(0.49, 1.83)	
	Atopic dermatitis N Total: 807	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: 162 N Cases: 24	OR Estimate: 1.21 95% CI(0.63, 2.35)	
	Atopic dermatitis N Total: 807	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: 175 N Cases: 22	OR Estimate: 0.98 95% CI(0.49, 2)	
	Atopic dermatitis N Total: 807	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: 162 N Cases: 21	OR Estimate: 0.9 95% CI(0.45, 1.81)	
	Atopic dermatitis N Total: 807	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: 174 N Cases: 22	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Atopic dermatitis N Total: 807	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: 155 N Cases: 24	OR Estimate: 1.24 95% CI(0.64, 2.42)	
	Atopic dermatitis N Total: 807	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: 163 N Cases: 24	OR Estimate: 1.1 95% CI(0.56, 2.17)	
	Atopic dermatitis N Total: 807	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: 164 N Cases: 21	OR Estimate: 1 95% CI(0.5, 1.98)	
	Atopic dermatitis N Total: 807	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: 151 N Cases: 20	OR Estimate: 0.92 95% CI(0.46, 1.86)	
	Eczema N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: NR N Cases: NR	OR	
	Eczema N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: NR N Cases: NR	OR Estimate: 0.94 95% CI(0.67, 1.31)	
	Eczema N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: NR N Cases: NR	OR Estimate: 1.03 95% CI(0.73, 1.44)	
	Eczema N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: NR N Cases: NR	OR Estimate: 0.77 95% CI(0.55, 1.09)	
	Eczema N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: NR N Cases: NR	OR Estimate: 0.81 95% CI(0.56, 1.15)	
	Eczema N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: NR N Cases: NR	OR	
	Eczema N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: NR N Cases: NR	OR Estimate: 1.04 95% CI(0.73, 1.47)	
	Eczema N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.8, 1.57)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Eczema N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: NR N Cases: NR	OR Estimate: 0.83 95% CI(0.58, 1.19)	
Eczema N Total: 951		6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: NR N Cases: NR	OR Estimate: 0.94 95% CI(0.66, 1.34)	
Eczema N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: NR N Cases: NR	OR	
Eczema N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: NR N Cases: NR	OR Estimate: 0.72 95% CI(0.51, 1)	
Eczema N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: NR N Cases: NR	OR Estimate: 0.68 95% CI(0.49, 0.96)	
Eczema N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: NR N Cases: NR	OR Estimate: 0.7 95% CI(0.49, 0.98)	
Eczema N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: NR N Cases: NR	OR Estimate: 0.6 95% CI(0.42, 0.87)	
Eczema N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: NR N Cases: NR	OR	
Eczema N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: NR N Cases: NR	OR Estimate: 1.21 95% CI(0.85, 1.73)	
Eczema N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: NR N Cases: NR	OR Estimate: 1.02 95% CI(0.71, 1.47)	
Eczema N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: NR N Cases: NR	OR Estimate: 1.3 95% CI(0.91, 1.85)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Eczema N Total: 951	6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: NR N Cases: NR	OR Estimate: 1.29 95% CI(0.91, 1.83)	
	High total IgE N Total: 776	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: 158 N Cases: 57	OR	
	High total IgE N Total: 776	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: 159 N Cases: 44	OR Estimate: 0.69 95% CI(0.42, 1.15)	
	High total IgE N Total: 776	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: 162 N Cases: 67	OR Estimate: 1.29 95% CI(0.8, 2.09)	
	High total IgE N Total: 776	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: 153 N Cases: 49	OR Estimate: 0.83 95% CI(0.5, 1.37)	
	High total IgE N Total: 776	24 months	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: 144 N Cases: 39	OR Estimate: 0.72 95% CI(0.42, 1.24)	
	High total IgE N Total: 776	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: 152 N Cases: 47	OR	
	High total IgE N Total: 776	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: 158 N Cases: 43	OR Estimate: 0.82 95% CI(0.5, 1.41)	
	High total IgE N Total: 776	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: 154 N Cases: 51	OR Estimate: 1.04 95% CI(0.63, 1.72)	
	High total IgE N Total: 776	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: 153 N Cases: 63	OR Estimate: 1.42 95% CI(0.86, 2.35)	
	High total IgE N Total: 776	24 months	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: 159 N Cases: 52	OR Estimate: 0.88 95% CI(0.53, 1.47)	
	High total IgE N Total: 776	24 months	Ratio n-6 LCPs (LGGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: 147 N Cases: 51	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	High total IgE N Total: 776	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: 150 N Cases: 46	OR Estimate: 0.83 95% CI(0.5, 1.39)	
	High total IgE N Total: 776	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: 155 N Cases: 53	OR Estimate: 0.97 95% CI(0.58, 1.61)	
	High total IgE N Total: 776	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: 169 N Cases: 50	OR Estimate: 0.84 95% CI(0.5, 1.42)	
	High total IgE N Total: 776	24 months	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: 155 N Cases: 56	OR Estimate: 1.02 95% CI(0.61, 1.71)	
	High total IgE N Total: 776	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: 169 N Cases: 63	OR	
	High total IgE N Total: 776	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: 149 N Cases: 44	OR Estimate: 0.74 95% CI(0.45, 1.22)	
	High total IgE N Total: 776	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: 156 N Cases: 54	OR Estimate: 0.93 95% CI(0.57, 1.52)	
	High total IgE N Total: 776	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: 159 N Cases: 48	OR Estimate: 0.79 95% CI(0.48, 1.3)	
	High total IgE N Total: 776	24 months	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: 143 N Cases: 47	OR Estimate: 0.88 95% CI(0.53, 1.46)	
	Wheeze N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -6.46 N Quantile: NR N Cases: NR	OR	
	Wheeze N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 6.47-7.15 N Quantile: NR N Cases: NR	OR Estimate: 1.23 95% CI(0.87, 1.73)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheeze N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 7.16-7.85 N Quantile: NR N Cases: NR	OR Estimate: 1.08 95% CI(0.78, 1.5)	
	Wheeze N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 7.86-8.6 N Quantile: NR N Cases: NR	OR Estimate: 1.08 95% CI(0.78, 1.49)	
	Wheeze N Total: 951	6-7 years	AA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 8.61- N Quantile: NR N Cases: NR	OR Estimate: 1.03 95% CI(0.74, 1.44)	
	Wheeze N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -60.72 N Quantile: NR N Cases: NR	OR	
	Wheeze N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 60.73-72.35 N Quantile: NR N Cases: NR	OR Estimate: 1.04 95% CI(0.76, 1.42)	
	Wheeze N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 72.36-82.29 N Quantile: NR N Cases: NR	OR Estimate: 0.87 95% CI(0.64, 1.19)	
	Wheeze N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 83.3-102.69 N Quantile: NR N Cases: NR	OR Estimate: 0.9 95% CI(0.66, 1.23)	
	Wheeze N Total: 951	6-7 years	Ratio LA to ALA n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 102.7- N Quantile: NR N Cases: NR	OR Estimate: 0.91 95% CI(0.68, 1.23)	
	Wheeze N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -1.91 N Quantile: NR N Cases: NR	OR	
	Wheeze N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 1.92-2.24 N Quantile: NR N Cases: NR	OR Estimate: 0.88 95% CI(0.63, 1.23)	
	Wheeze N Total: 951	6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 2.25-2.52 N Quantile: NR N Cases: NR	OR Estimate: 1.03 95% CI(0.75, 1.42)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Wheeze N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 2.53-2.84 N Quantile: NR N Cases: NR	OR Estimate: 0.83 95% CI(0.59, 1.18)	
Wheeze N Total: 951		6-7 years	Ratio n-6 LCPs (LGLA and AA) to n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 2.85- N Quantile: NR N Cases: NR	OR Estimate: 0.97 95% CI(0.7, 1.35)	
Wheeze N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q1 -3.93 N Quantile: NR N Cases: NR	OR	
Wheeze N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q2 3.94-4.44 N Quantile: NR N Cases: NR	OR Estimate: 0.96 95% CI(0.7, 1.31)	
Wheeze N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q3 4.45-4.93 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.82, 1.53)	
Wheeze N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q4 4.94-5.64 N Quantile: NR N Cases: NR	OR Estimate: 1.15 95% CI(0.85, 1.57)	
Wheeze N Total: 951		6-7 years	n-3 LCPs (EPA, DPA n-3, DHA) n-3 Measure: maternal venous plasma phospholipids n-3 Units: wt%	Q5 5.65- N Quantile: NR N Cases: NR	OR Estimate: 0.98 95% CI(0.7, 1.37)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Nwaru, et al., 2012¹⁸⁰</p> <p>Study name: Finnish Type 1 Diabetes Prediction and Prevention Nutrition Study</p> <p>Study dates: Infants recruited between 20 October 1997 and 29 February 2004; Follow-up to 5 years of age</p> <p>Study design: Observational prospective</p> <p>Location: Finland</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p> <p>Follow-up: 5 years</p>	<p>Study Population: NR</p> <p>Pregnant enrolled NR Pregnant completers 3523</p> <p>Infants enrolled 3253 Infants completers 2441</p> <p>Infant age: birth</p> <p>Race of Mother: White European (100%)</p>	<p>Inclusion Criteria: Newborn infants with human leucocyte antigen (HLA)- conferred susceptibility to type 1 diabetes recruited from three university hospitals in Finland</p> <p>Exclusion Criteria: Infants with severe systemic disease or anomalies, or both parents non-Caucasian</p>	<p>Adjustments: Sex of child, hospital of birth, duration of gestation, maternal age at delivery, maternal basic education, maternal smoking during pregnancy, mode of delivery, number of siblings at the time of the child's birth, parental asthma, parental allergic rhinitis, pets at home by 1 year of age. A second adjusted model was computed for the FA in which potentially confounding nutrients, vitamin C, Zn, Se, vitamin D and vitamin E were included as additional covariates</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Nwaru 2012 ¹⁸⁰	Allergic rhinitis N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -4.45 N Quantile: NR N Cases: NR	OR Estimate: 1.01 95% CI(0.79, 1.29)	
	Allergic rhinitis N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 4.45-6.4 N Quantile: NR N Cases: NR	OR	
	Allergic rhinitis N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 6.4-8.9 N Quantile: NR N Cases: NR	OR Estimate: 0.74 95% CI(0.56, 0.99)	
	Allergic rhinitis N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -0.19 N Quantile: NR N Cases: NR	OR Estimate: 0.94 95% CI(0.72, 1.22)	
	Allergic rhinitis N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 0.19-0.6 N Quantile: NR N Cases: NR	OR	
	Allergic rhinitis N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.6-3.5 N Quantile: NR N Cases: NR	OR Estimate: 0.93 95% CI(0.72, 1.21)	
	Allergic rhinitis N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -0.07 N Quantile: NR N Cases: NR	OR Estimate: 0.99 95% CI(0.76, 1.29)	
	Allergic rhinitis N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 0.07-0.23 N Quantile: NR N Cases: NR	OR	
	Allergic rhinitis N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.23-1.25 N Quantile: NR N Cases: NR	OR Estimate: 0.99 95% CI(0.76, 1.28)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic rhinitis N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 NR-NR N Quantile: NR N Cases: NR	OR Estimate: 1.09 95% CI(0.84, 1.43)	
	Allergic rhinitis N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 NR-NR N Quantile: NR N Cases: NR	OR	
	Allergic rhinitis N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 NR-NR N Quantile: NR N Cases: NR	OR Estimate: 1.35 95% CI(1.05, 1.73)	
	Allergic rhinitis N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -5.55 N Quantile: NR N Cases: NR	OR Estimate: 0.89 95% CI(0.69, 1.15)	
	Allergic rhinitis N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 5.55-7.34 N Quantile: NR N Cases: NR	OR	
	Allergic rhinitis N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 7.35-11.28 N Quantile: NR N Cases: NR	OR Estimate: 0.82 95% CI(0.63, 1.08)	
	Atopic eczema N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -4.45 N Quantile: NR N Cases: NR	OR Estimate: 1.05 95% CI(0.86, 1.3)	
	Atopic eczema N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 4.45-6.4 N Quantile: NR N Cases: NR	OR	
	Atopic eczema N Total: 2441	5 years	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 6.4-8.9 N Quantile: NR N Cases: NR	OR Estimate: 0.99 95% CI(0.8, 1.23)	
	Atopic eczema N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -0.19 N Quantile: NR N Cases: NR	OR Estimate: 1.18 95% CI(0.95, 1.46)	
	Atopic eczema N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 0.19-0.6 N Quantile: NR N Cases: NR	OR	
	Atopic eczema N Total: 2441	5 years	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.6-3.5 N Quantile: NR N Cases: NR	OR Estimate: 0.98 95% CI(0.79, 1.2)	
	Atopic eczema N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -0.07 N Quantile: NR N Cases: NR	OR Estimate: 1.07 95% CI(0.86, 1.33)	
	Atopic eczema N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 0.07-0.23 N Quantile: NR N Cases: NR	OR	
	Atopic eczema N Total: 2441	5 years	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.23-1.25 N Quantile: NR N Cases: NR	OR Estimate: 0.94 95% CI(0.76, 1.16)	
	Atopic eczema N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 NR-NR N Quantile: NR N Cases: NR	OR Estimate: 0.99 95% CI(0.8, 1.22)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Atopic eczema N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 NR-NR N Quantile: NR N Cases: NR	OR	
	Atopic eczema N Total: 2441	5 years	Ratio of n-6 to n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 NR-NR N Quantile: NR N Cases: NR	OR Estimate: 1.01 95% CI(0.82, 1.24)	
	Atopic eczema N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 -5.55 N Quantile: NR N Cases: NR	OR Estimate: 1.03 95% CI(0.84, 1.27)	
	Atopic eczema N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 & Q3 5.55-7.34 N Quantile: NR N Cases: NR	OR	
	Atopic eczema N Total: 2441	5 years	n-3 PUFA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 7.35-11.28 N Quantile: NR N Cases: NR	OR Estimate: 0.93 95% CI(0.75, 1.14)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Oken, et al., 2004⁴⁶</p> <p>Study name: Project Viva</p> <p>Study dates: 1999-2002</p> <p>Study design: Observational prospective</p> <p>Location: US</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 2109 Pregnant completers 2109</p> <p>Pregnant age: 14-<20, 3% 20-<25, 6% 25-<30, 21% 30-<35, 42% 35=<40, 23% >=40, 4% (14-44)</p> <p>Race of Mother: White European (66) Black (16) Asian (6) Hispanic (7) Other race/ethnicity (4)</p>	<p>Inclusion Criteria: delivered a live infant, and completed at least one dietary questionnaire</p> <p>Exclusion Criteria: taking cod liver or fish oil supplement</p>	<p>Adjustments: Enrollment site, infant sex, and maternal age, height, intrapartum weight gain, pre-pregnancy BMI, race/ethnicity, smoking during pregnancy, education, and gravidity</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Oken 2004 ⁴⁶	Birth weight N Total: 1663		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q1 0.02 N Quantile: 416 N Cases: NR	50 95% CI(-19, 119)	
	Birth weight N Total: 1663		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q2 0.09 N Quantile: 416 N Cases: NR	49 95% CI(-19, 117)	
	Birth weight N Total: 1663		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q3 0.18 N Quantile: 416 N Cases: NR	-23 95% CI(-92, 47)	
	Birth weight N Total: 1663		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q4 0.38 N Quantile: 416 N Cases: NR		
	Birth weight N Total: 1797		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q1 0.02 N Quantile: 449 N Cases: NR	94 95% CI(23, 166)	
	Birth weight N Total: 1797		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q2 0.09 N Quantile: 449 N Cases: NR	35 95% CI(-36, 107)	
	Birth weight N Total: 1797		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q3 0.18 N Quantile: 449 N Cases: NR	32 95% CI(-39, 103)	
	Birth weight N Total: 1797		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q4 0.36 N Quantile: 449 N Cases: NR		
	Birth weight N Total: 2070		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q1+Q2 0.05 N Quantile: 1035 N Cases: NR	90 95% CI(33, 147)	
	Birth weight N Total: 2070		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q3 0.09 N Quantile: 518 N Cases: NR	11 95% CI(-58, 81)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Birth weight N Total: 2070		DHA+EPA n-3 Measure: FFQ n-3 Units: g/day	Q4 0.27 N Quantile: 518 N Cases: NR		
	Length of gestation N Total: 1663		DHA+EPA @ 2nd trimester n-3 Measure: FFQ n-3 Units: g/day	Q1 0.02 N Quantile: 416 N Cases: NR	Q1-Q4 (difference in weeks) Estimate: 0.3 95% CI(-1.4, 2.1)	
	Length of gestation N Total: 1663		DHA+EPA @ 2nd trimester n-3 Measure: FFQ n-3 Units: g/day	Q2 0.09 N Quantile: 416 N Cases: NR	Q2-Q4 (difference in weeks) Estimate: -0.4 95% CI(-2.1, 1.3)	
	Length of gestation N Total: 1663		DHA+EPA @ 2nd trimester n-3 Measure: FFQ n-3 Units: g/day	Q3 0.18 N Quantile: 416 N Cases: NR	Q3-Q4 (difference in weeks) Estimate: 0.3 95% CI(-1.4, 2)	
	Length of gestation N Total: 1663		DHA+EPA @ 2nd trimester n-3 Measure: FFQ n-3 Units: g/day	Q4 0.38 N Quantile: 416 N Cases: NR		
	Length of gestation N Total: 1797		DHA+EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: g/day	Q1 0.02 N Quantile: 449 N Cases: NR	Q1-Q4 (difference in weeks) Estimate: 0.3 95% CI(-1.3, 19)	
	Length of gestation N Total: 1797		DHA+EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: g/day	Q1 vs. Q4	OR Estimate: 1.1 95% CI(0.7, 1.9)	
	Length of gestation N Total: 1797		DHA+EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: g/day	Q2 0.09 N Quantile: 449 N Cases: NR	Q2-Q4 (difference in weeks) Estimate: -0.3 95% CI(-1.9, 1.3)	
	Length of gestation N Total: 1797		DHA+EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: g/day	Q3 0.18 N Quantile: 449 N Cases: NR	Q3-Q4 (difference in weeks) Estimate: 0.6 95% CI(-1, 2.2)	
	Length of gestation N Total: 1797		DHA+EPA @ 1st trimester n-3 Measure: FFQ n-3 Units: g/day	Q4 0.36 N Quantile: 449 N Cases: NR		
	Length of gestation N Total: 2070		DHA+EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: g/day	Q1+Q2 0.05 N Quantile: 1035 N Cases: NR	Q1+Q2-Q4 (difference in weeks) Estimate: 0.5 95% CI(-0.7, 1.7)	
	Length of gestation N Total: 2070		DHA+EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: g/day	Q3 0.09 N Quantile: 518 N Cases: NR	Q3-Q4 (difference in weeks) Estimate: -0.7 95% CI(-2.2, 0.8)	
	Length of gestation N Total: 2070		DHA+EPA @ 3rd trimester n-3 Measure: FFQ n-3 Units: g/day	Q4 0.27 N Quantile: 518 N Cases: NR		

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Oken, et al., 2007⁶⁹</p> <p>Study name: Project Viva</p> <p>Study dates: Recruitment 1999-2002</p> <p>Study design: Observational prospective</p> <p>Location: US</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 2,128 Pregnant completers 1,718</p> <p>Pregnant age: 93% were 20-40 years</p> <p>Race of Mother: White European (72%) Black (12%) Hispanic (6%) Other race/ethnicity (10%)</p>	<p>Inclusion Criteria: 1st trimester pregnant women attending 1st prenatal visit</p> <p>Exclusion Criteria: Post hoc: no live birth, no medical records, failure to complete dietary questionnaires, pre-existing chronic hypertension and no subsequent preeclampsia</p>	<p>Adjustments: Maternal age, pre-pregnancy BMI, 1st trimester sBp, race/ethnicity, education, parity; nutrients adjusted for total energy intake</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Oken 2007 ⁶⁹	Gestational HTN N Total: 1718	Term	AA n-3 Measure: FFQ n-3 Units: per 100 mg	N Quantile: NR N Cases: 119	OR Estimate: 1.03 95% CI(0.97, 1.1)	
	Gestational HTN N Total: 1718	Term	ALA n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 119	OR Estimate: 1.14 95% CI(0.68, 1.92)	
	Gestational HTN N Total: 1718	Term	DHA+EPA/AA n-3 Measure: calculated n-3 Units: ratio	N Quantile: NR N Cases: 119	OR Estimate: 0.99 95% CI(0.93, 1.07)	
	Gestational HTN N Total: 1718	Term	DHA+EPA n-3 Measure: FFQ n-3 Units: per 100 mg	N Quantile: NR N Cases: 119	OR Estimate: 1.01 95% CI(0.95, 1.08)	
	Gestational HTN N Total: 1718	Term	LA n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 119	OR Estimate: 1.01 95% CI(0.95, 1.08)	
	Gestational HTN N Total: 1718	Term	Total n-3 n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 119	OR Estimate: 1.13 95% CI(0.79, 1.61)	
	Gestational HTN N Total: 1718	Term	n-3/n-6 n-3 Measure: calculated n-3 Units: ratio	N Quantile: NR N Cases: 119	OR Estimate: 1.02 95% CI(0.96, 1.08)	
	Preeclampsia N Total: 1718	Term	AA n-3 Measure: FFQ n-3 Units: per 100 mg	N Quantile: NR N Cases: 59	OR Estimate: 0.99 95% CI(0.91, 1.08)	
	Preeclampsia N Total: 1718	Term	ALA n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 59	OR Estimate: 1.35 95% CI(0.66, 2.74)	
	Preeclampsia N Total: 1718	Term	DHA+EPA/AA n-3 Measure: calculated n-3 Units: ratio	N Quantile: NR N Cases: 59	OR Estimate: 0.82 95% CI(0.66, 1.01)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Preeclampsia N Total: 1718	Term	DHA+EPA n-3 Measure: FFQ n-3 Units: per 100 mg	N Quantile: NR N Cases: 59	OR Estimate: 0.84 95% CI(0.69, 1.03)	
	Preeclampsia N Total: 1718	Term	LA n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 59	OR Estimate: 0.99 95% CI(0.91, 1.08)	
	Preeclampsia N Total: 1718	Term	Total n-3 n-3 Measure: FFQ n-3 Units: per g	N Quantile: NR N Cases: 59	OR Estimate: 1.01 95% CI(0.55, 1.85)	
	Preeclampsia N Total: 1718	Term	n-3/n-6 n-3 Measure: calculated n-3 Units: ratio	N Quantile: NR N Cases: 59	OR Estimate: 0.99 95% CI(0.89, 1.11)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Olafsdottir, et al., 2005⁸²</p> <p>Study dates: 1999-2001</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 436 Pregnant completers 436</p> <p>Pregnant age: No 27.8; Yes 29.6 (no 4.9; yes 4.6)</p> <p>Race of Mother: NR</p>	<p>Inclusion Criteria: absence of pre-eclampsia, hypertension or diabetes mellitus</p> <p>Exclusion Criteria: women whose personal data could not be found or who moved abroad before giving birth (n 8), had a miscarriage or stillbirth (n 17), twins or triplets (n 5), a preterm birth hypertension/pre-eclampsia (n 62) or gestational diabetes mellitus (n=4)</p>	<p>Adjustments: Gender, gestational age, mother's height, BMI, hemoglobin, alcohol consumption in first trimester, parity, smoking during pregnancy, weight gain during pregnancy</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Olafsdottir 2005 ⁸²	Birth weight N Total: 350		Liquid cod liver oil in first trimester (y/n) n-3 Measure: FFQ n-3 Units: grams	Yes vs. no N Quantile: NR N Cases: NR	Coefficient Estimate: 132.1 95% CI(18.3, 246)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Olafsdottir, et al., 2006⁷⁰</p> <p>Study dates: 1999-2001</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Government, Multiple foundations and Societies</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 549 Pregnant completers 488</p> <p>Pregnant age: 28 (5)</p> <p>Race of Mother: White European (NR)</p>	<p>Inclusion Criteria: Pregnant women attending first prenatal visit at Center of Prenatal Care in Reykjavik from 1999-2001, who gave birth to full-term babies completed the study.</p> <p>Exclusion Criteria: Essential hypertension, gestational diabetes, miscarriage/stillbirth, twins/triplets, preterm birth, loss of personal data, moved, missing data,</p>	<p>Adjustments: Weight gain during pregnancy, BMI X weight gain, smoking, parity and diastolic and systolic blood pressure early in pregnancy</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Olafsdottir 2005 ⁷⁰	Gestational hypertension or preeclampsia		n-3 LCPUFAs (0.1-0.23g/d) n-3 Units: g/d	11th-50th N Cases: NR	OR	
	Gestational hypertension or preeclampsia		n-3 LCPUFAs (0.24-0.87g/d) n-3 Units: g/d	51st-90th N Cases: NR	OR	
	Gestational hypertension or preeclampsia		n-3 LCPUFAs (<0.9g/d) n-3 Units: g/d	10th centile N Cases: NR	OR	
	Gestational hypertension or preeclampsia		n-3 LCPUFAs (>0.87g/d) n-3 Units: g/d	>90th N Cases: NR	OR	
	Gestational hypertension or preeclampsia N Total: 488		n-3 LCPUFAs n-3 Units: yes/no	All N Cases: 49	OR Estimate: 4.7 95% CI(1.8, 12.6)	
	Gestational hypertension N Total: 488		Cod liver oil liquid n-3 Measure: FFQ yes/no n-3 Units: yes/no	All N Cases: 30	OR Estimate: 5.2 95% CI(1.5, 17.8)	
	Preeclampsia N Total: 488		Yes/no	All N Cases: 19	OR Estimate: 4.2 95% CI(0.8, 20.9)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Parker, et al., 2015 ⁹⁷ Study dates: NR Study design: Observational prospective Location: Australia Funding source / conflict: Government	Study Population: Healthy pregnant women Postpartum women Pregnant enrolled 1232 Pregnant completers 831 Pregnant age: 31.0 (5.7) Race of Mother: NR (100)	Inclusion Criteria: Women between 34 and 37 weeks of pregnancy and attending an obstetric service. Participants had to be more than 18 years of age, be proficient in English and able to provide informed consent Exclusion Criteria: nr	Adjustments: Age, education level, income level, marital status, number of children, neuroticism scores, the presence or absence of a lifetime mood disorder, coffee drinking, cigarette smoking and alcohol intake, as well as stress levels during pregnancy

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Parker 2015 ⁹⁷	Postnatal depression measured by EPDS N Total: 773		PUFA variables: total omega-6; total omega-3; omega-6/omega-3 ratio; DHA; DPA; DPE; EPA+DHA; AA n-3 Measure: Maternal RBC phospholipids at 36 weeks of pregnancy n-3 Units: percentage of total fatty acids in erythrocyte phospholipids	NR N Cases: 138	OR	
	Postnatal depression measured by MINIAD N Total: 819		PUFA variables: total omega-6; total omega-3; omega-6/omega-3 ratio; DHA; DPA; DPE; EPA+DHA; AA n-3 Measure: Maternal RBC phospholipids at 36 weeks of pregnancy n-3 Units: percentage of total fatty acids in erythrocyte phospholipids	NR N Cases: 87	OR	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Pike, et al., 2012 ¹⁸⁶ Study name: Southampton Women's Survey Study dates: 2006-2010 Study design: Observational prospective Location: UK Funding source / conflict: Government, Some authors serve on scientific advisory boards for corporations Follow-up: Birth to 6 years	Study Population: Healthy infants Pregnant enrolled Infants enrolled 1485 Infants completers 865 Pregnant age: 30.4 (3.8) Race of Mother: NR (100)	Inclusion Criteria: mothers and children in the Southampton Women's Survey Exclusion Criteria: Infants born = 35 weeks' gestation were excluded to avoid abnormal lung development associated with prematurity	Adjustments: Child's age, maternal asthma, and paternal rhinitis for airway inflammation outcome

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Pike 2012 ¹⁸⁶	Airway inflammation N Total: 452	6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.108 95% CI(0.014, 0.201)	
	Airway inflammation N Total: 452	6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: -0.05 95% CI(-0.144, 0.044)	
	Airway inflammation N Total: 452	6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.095 95% CI(0.002, 0.189)	
	Airway inflammation N Total: 452	6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: -0.022 95% CI(-0.119, 0.074)	
	Airway inflammation N Total: 452	6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.042 95% CI(-0.052, 0.135)	
	Airway inflammation N Total: 452	6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.039 95% CI(-0.053, 0.131)	
	Atopy N Total: 638	6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1.1 95% CI(0.96, 1.26)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Atopy N Total: 638		6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.99 95% CI(0.86, 1.14)	
Atopy N Total: 638		6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1 95% CI(0.87, 1.14)	
Atopy N Total: 638		6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.94 95% CI(0.83, 1.06)	
Atopy N Total: 638		6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.99 95% CI(0.87, 1.13)	
Atopy N Total: 638		6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1 95% CI(0.88, 1.14)	
Lung function N Total: 702		6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0 95% CI(-0.014, 0.015)	
Lung function N Total: 702		6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: -0.009 95% CI(-0.024, 0.005)	
Lung function N Total: 702		6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.008 95% CI(-0.006, 0.022)	
Lung function N Total: 702		6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.013 95% CI(-0.001, 0.027)	
Lung function N Total: 702		6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.01 95% CI(-0.004, 0.024)	
Lung function N Total: 702		6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.01 95% CI(-0.004, 0.024)	
Persistent/late wheeze with atopy N Total: 861		6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1.06 95% CI(0.82, 1.36)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Persistent/late wheeze with atopy N Total: 861	6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.91 95% CI(0.7, 1.19)	
	Persistent/late wheeze with atopy N Total: 861	6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.74 95% CI(0.55, 1)	
	Persistent/late wheeze with atopy N Total: 861	6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.65 95% CI(0.43, 0.98)	
	Persistent/late wheeze with atopy N Total: 861	6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.72 95% CI(0.54, 0.96)	
	Persistent/late wheeze with atopy N Total: 861	6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.73 95% CI(0.54, 0.99)	
	Persistent/late wheeze without atopy N Total: 861	6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.76 95% CI(0.6, 0.96)	
	Persistent/late wheeze without atopy N Total: 861	6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1.17 95% CI(0.87, 1.58)	
	Persistent/late wheeze without atopy N Total: 861	6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.67 95% CI(0.49, 0.93)	
	Persistent/late wheeze without atopy N Total: 861	6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.57 95% CI(0.37, 0.89)	
	Persistent/late wheeze without atopy N Total: 861	6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.69 95% CI(0.51, 0.95)	
	Persistent/late wheeze without atopy N Total: 861	6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.73 95% CI(0.53, 0.99)	
	Persistent/late wheeze N Total: 861	6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.88 95% CI(0.76, 1.02)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Persistent/late wheeze N Total: 861	6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1.09 95% CI(0.96, 1.24)	
	Persistent/late wheeze N Total: 861	6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.91 95% CI(0.76, 1.08)	
	Persistent/late wheeze N Total: 861	6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.91 95% CI(0.73, 1.14)	
	Persistent/late wheeze N Total: 861	6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.93 95% CI(0.79, 1.11)	
	Persistent/late wheeze N Total: 861	6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.94 95% CI(0.79, 1.12)	
	Transient wheeze N Total: 861	6 years	AA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.94 95% CI(0.88, 1.02)	
	Transient wheeze N Total: 861	6 years	ALA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 1.06 95% CI(0.98, 1.14)	
	Transient wheeze N Total: 861	6 years	DHA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.95 95% CI(0.88, 1.03)	
	Transient wheeze N Total: 861	6 years	EPA% n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.98 95% CI(0.92, 1.06)	
	Transient wheeze N Total: 861	6 years	Total n-3 PUFAs n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.97 95% CI(0.9, 1.04)	
	Transient wheeze N Total: 861	6 years	Total n-3:n-6 n-3 Measure: Maternal plasma phosphatidylcholine at 34 weeks gestation n-3 Units: % total fatty acids	All	RR Estimate: 0.98 95% CI(0.92, 1.05)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Saito, et al., 2010¹⁸¹</p> <p>Study name: Osaka maternal and child health study</p> <p>Study dates: Recruitment: November 2001 to March 2003 Follow-up: 3-4 months</p> <p>Study design: Observational prospective</p> <p>Location: Japan</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 3-4 months</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant completers 771</p> <p>Infants completers 771</p> <p>Pregnant age: 29.9 (4.0)</p> <p>Race of Mother: NR (100%)</p>	<p>Inclusion Criteria: Pregnant women living in Neyagawa City (one of the 43 municipalities in Osaka Prefecture) and a few municipalities other than Neyagawa</p> <p>Exclusion Criteria: Survey completed outside 3-5 month postpartum window</p>	<p>Adjustments: Maternal age, gestation at baseline, family income, maternal and paternal education, maternal and paternal history of asthma, atopic eczema and allergic rhinitis, mite allergen level from maternal bedclothes, vacuuming living room, mold in kitchen, changes in maternal diet in the previous 1 month, season when data at baseline were collected, baby's older siblings, baby's sex, baby's birth weight, breastfeeding and bathing or showering infant.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Yokoyama 2010 ¹⁸¹	Atopic eczema N Total: 771	3-5 months	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 1.3 N Quantile: 192 N Cases: 13	OR	
	Atopic eczema N Total: 771	3-5 months	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 1.6 N Quantile: 193 N Cases: 19	OR Estimate: 1.59 95% CI(0.73, 3.57)	
	Atopic eczema N Total: 771	3-5 months	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q3 1.9 N Quantile: 193 N Cases: 23	OR Estimate: 2.26 95% CI(1.06, 5.03)	
	Atopic eczema N Total: 771	3-5 months	ALA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 2.3 N Quantile: 193 N Cases: 10	OR Estimate: 0.76 95% CI(0.3, 1.87)	
	Atopic eczema N Total: 771	3-5 months	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 0.15 N Quantile: 192 N Cases: 16	OR	
	Atopic eczema N Total: 771	3-5 months	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 0.24 N Quantile: 193 N Cases: 14	OR Estimate: 0.96 95% CI(0.43, 2.11)	
	Atopic eczema N Total: 771	3-5 months	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q3 0.31 N Quantile: 193 N Cases: 16	OR Estimate: 0.93 95% CI(0.42, 2.05)	
	Atopic eczema N Total: 771	3-5 months	DHA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.46 N Quantile: 193 N Cases: 19	OR Estimate: 1.43 95% CI(0.68, 3.07)	
	Atopic eczema N Total: 771	3-5 months	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 0.07 N Quantile: 192 N Cases: 13	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Atopic eczema N Total: 771	3-5 months	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 0.13 N Quantile: 193 N Cases: 20	OR Estimate: 1.57 95% CI(0.72, 3.53)	
	Atopic eczema N Total: 771	3-5 months	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q3 0.18 N Quantile: 193 N Cases: 13	OR Estimate: 0.98 95% CI(0.41, 2.31)	
	Atopic eczema N Total: 771	3-5 months	EPA n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.27 N Quantile: 193 N Cases: 19	OR Estimate: 1.84 95% CI(0.84, 4.15)	
	Atopic eczema N Total: 771	3-5 months	n-3 Polyunsaturated fatty acids n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 1.71 N Quantile: 192 N Cases: 13	OR	
	Atopic eczema N Total: 771	3-5 months	n-3 Polyunsaturated fatty acids n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 2.1 N Quantile: 193 N Cases: 22	OR Estimate: 2.06 95% CI(0.97, 4.55)	
	Atopic eczema N Total: 771	3-5 months	n-3 Polyunsaturated fatty acids n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q3 2.5 N Quantile: 193 N Cases: 14	OR Estimate: 1.33 95% CI(0.57, 3.11)	
	Atopic eczema N Total: 771	3-5 months	n-3 Polyunsaturated fatty acids n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 3 N Quantile: 193 N Cases: 16	OR Estimate: 1.45 95% CI(0.64, 3.31)	
	Atopic eczema N Total: 771	3-5 months	n-3/n-6 Polyunsaturated fatty acid ratio n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q1 0.17 N Quantile: 192 N Cases: 15	OR	
	Atopic eczema N Total: 771	3-5 months	n-3/n-6 Polyunsaturated fatty acid ratio n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q2 0.19 N Quantile: 193 N Cases: 16	OR Estimate: 0.95 95% CI(0.43, 2.11)	
	Atopic eczema N Total: 771	3-5 months	n-3/n-6 Polyunsaturated fatty acid ratio n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q3 0.21 N Quantile: 193 N Cases: 19	OR Estimate: 1.27 95% CI(0.59, 2.78)	
	Atopic eczema N Total: 771	3-5 months	n-3/n-6 Polyunsaturated fatty acid ratio n-3 Measure: Intake (FFQ) n-3 Units: g/d	Q4 0.24 N Quantile: 193 N Cases: 15	OR Estimate: 1.17 95% CI(0.52, 2.62)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Sallis, et al., 2014⁹⁶</p> <p>Study name: Avon Longitudinal Study of Parents and Children (ALSPAC)</p> <p>Study dates: 1991-1992</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Industry, Government</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 14,541 Pregnant withdrawals 11,144 Pregnant completers 3,397</p> <p>Pregnant age: 28.9 (4.5) not reported</p> <p>Race of Mother: White European (100%)</p>	<p>Inclusion Criteria: All women with an expected due date between April 1991 and December 1992 were eligible for the study. Only women with data available on genotype, FA levels and depressive symptoms during pregnancy or at 8 weeks postnatally and women with a self-reported ethnicity of White European were included in this analysis.</p> <p>Exclusion Criteria: Mothers who lost a child during the neonatal period and those with a still birth; mothers with multiple births.</p>	<p>Adjustments: Social class (I/II, III or IV/V) and maternal age</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Sallis 2014 ⁹⁶	Antenatal depression N Total: 2911		EPA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All N Cases: 441	OR Estimate: 0.97 95% CI(0.91, 1.04)	
	Antenatal depression N Total: 2912		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	OR Estimate: 0.99 95% CI(0.91, 1.07)	
	Antenatal depression N Total: 2912		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	RD Estimate: 0.05 95% CI(-0.09, 0.19)	
	Perinatal onset depression N Total: 2377		EPA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All N Cases: 306	OR Estimate: 1.07 95% CI(0.99, 1.15)	
	Perinatal onset depression N Total: 2378		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	OR Estimate: 1.08 95% CI(0.98, 1.19)	
	Perinatal onset depression N Total: 2378		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	RD Estimate: 0.08 95% CI(-0.05, 0.22)	
	Postnatal depression N Total: 2756		EPA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All N Cases: 265	OR Estimate: 1.04 95% CI(0.96, 1.13)	
	Postnatal depression N Total: 2757		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	OR Estimate: 1.04 95% CI(0.94, 1.15)	
	Postnatal depression N Total: 2757		DHA n-3 Measure: Maternal red blood cells n-3 Units: % total RBC phospholipid	All	RD Estimate: 0.02 95% CI(-0.08, 0.13)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Scholtens, et al., 2009¹⁰³</p> <p>Study name: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study</p> <p>Study dates: Recruitment: 1996-1997 Follow-up: 1 year</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Industry, Government, Multiple foundations and Societies, None</p> <p>Follow-up: 1 year</p> <p>Original, same study, or follow-up studies: Study described in Brunekreef, 2002</p>	<p>Study Population: NR</p> <p>Pregnant enrolled 4146</p> <p>Infants enrolled 276 Infants completers 244</p> <p>Infant age: Birth</p> <p>Race of Mother: NR (NR)</p>	<p>Inclusion Criteria: Children of mothers recruited from the general population during pregnancy</p> <p>Exclusion Criteria: None reported</p>	<p>Adjustments: Age of child at breast-milk collection and total breast-feeding duration</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Scholtens 2008 ¹⁰³	Mean BMI gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.002 95% CI(0.002, -0.01)	
	Mean BMI gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.007 95% CI(0.007, -0.004)	
	Mean BMI gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.004 95% CI(0.004, -0.008)	
	Mean BMI gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.009 95% CI(0.009, -0.003)	
	Mean BMI gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.003 95% CI(-0.003, -0.015)	
	Mean BMI gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.004 95% CI(-0.004, -0.015)	
	Mean BMI gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.009 95% CI(-0.009, -0.021)	
	Mean BMI gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.01 95% CI(-0.01, -0.021)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Mean BMI gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.001 95% CI(-0.001, -0.013)	
	Mean BMI gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.008 95% CI(0.008, -0.004)	
	Mean length gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.011 95% CI(-0.011, -0.029)	
	Mean length gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.01 95% CI(-0.01, -0.028)	
	Mean length gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.013 95% CI(-0.013, -0.031)	
	Mean length gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.006 95% CI(0.006, 0.024)	
	Mean length gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.007 95% CI(0.007, -0.011)	
	Mean length gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.01 95% CI(0.01, -0.008)	
	Mean length gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.009 95% CI(0.009, -0.008)	
	Mean length gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.016 95% CI(0.016, 0.001)	
	Mean length gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.002 95% CI(-0.002, -0.02)	
	Mean length gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.004 95% CI(-0.004, -0.022)	
	Mean weight gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -1.64 95% CI(-1.64, -6.596)	
	Mean weight gain N Total: 244	1 y	ALA (18 : 3n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.697 95% CI(0.697, -4.275)	
	Mean weight gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.606 95% CI(0.606, -4.387)	
	Mean weight gain N Total: 244	1 y	DHA (22 : 6n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 0.833 95% CI(0.833, -4.124)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Mean weight gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 2.434 95% CI(2.434, -2.516)	
	Mean weight gain N Total: 244	1 y	EPA (20 : 5n-3) n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 3.187 95% CI(3.187, -1.776)	
	Mean weight gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.329 95% CI(-0.329, -5.282)	
	Mean weight gain N Total: 244	1 y	Total n-3 LCPUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -1.574 95% CI(-1.574, 6.532)	
	Mean weight gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: -0.253 95% CI(-0.253, -5.216)	
	Mean weight gain N Total: 244	1 y	Total n-3 PUFA n-3 Measure: Breast milk wt% n-3 Units: wt%		Coefficient Estimate: 2.843 95% CI(2.843, -2.17)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Smits, et al., 2013⁷³</p> <p>Study name: Amsterdam Born Children and their Development (ABCD)</p> <p>Study dates: Jan 2003- Mar 2004</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: None</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Pregnant enrolled 1659 Pregnant completers 1659</p> <p>Infants enrolled 1659 Infants completers 1659</p> <p>Pregnant age: <25 y, 5.7% 25-34 y, 61.2% >=35 y, 33.1%</p> <p>Infant age: 40.0 weeks (1.2)</p> <p>Race of Mother: White European (88.4)</p>	<p>Inclusion Criteria: NR</p> <p>Exclusion Criteria: primiparous women or delivered preterm</p>	<p>Adjustments: Potential confounding factors were evaluated but none of them was significant confounding defined as changing the odds ratio by 10%</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Smits 2015 ⁷³	Birth weight N Total: 1659		DHA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q1 <3.74 - N Quantile: NR N Cases: NR	-118.2 95% CI(-195.032, -41.368)	
	Birth weight N Total: 1659		DHA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q2 3.74 - 4.35 N Quantile: NR N Cases: NR	-43.8 95% CI(-120.632, 33.032)	
	Birth weight N Total: 1659		DHA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q3 4.35 - 4.86 N Quantile: NR N Cases: NR		
	Birth weight N Total: 1659		DHA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q4 4.88 - 5.54 N Quantile: NR N Cases: NR	-34.4 95% CI(-111.232, 42.432)	
	Birth weight N Total: 1659		DHA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q5 >=5.54 - N Quantile: NR N Cases: NR	-15.4 95% CI(-92.232, 61.432)	
	Birth weight N Total: 1659		EPA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q1 <0.33 - N Quantile: NR N Cases: NR	-182.5 95% CI(-258.94, -106.06)	
	Birth weight N Total: 1659		EPA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q2 0.33 - 0.46 N Quantile: NR N Cases: NR	-66.1 95% CI(-142.54, 10.34)	
	Birth weight N Total: 1659		EPA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q3 0.46 - 0.58 N Quantile: NR N Cases: NR		

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Birth weight N Total: 1659		EPA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q4 0.58 - 0.81 N Quantile: NR N Cases: NR	18.4 95% CI(-57.844, 94.644)	
	Birth weight N Total: 1659		EPA n-3 Measure: Maternal plasma phospholipids at early pregnancy n-3 Units: mg/L	Q5 >=0.81 - N Quantile: NR N Cases: NR	-26.6 95% CI(-103.04, 49.84)	
	SGA N Total: 1659		DHA n-3 Measure: Biomarker n-3 Units: mg/L	Q1 <3.74 - N Quantile: 332 N Cases: 44	OR Estimate: 1.11 95% CI(0.7, 1.75)	
	SGA N Total: 1659		DHA n-3 Measure: Biomarker n-3 Units: mg/L	Q2 3.74 - 4.35 N Quantile: 332 N Cases: 42	OR Estimate: 1.05 95% CI(0.66, 1.67)	
	SGA N Total: 1659		DHA n-3 Measure: Biomarker n-3 Units: mg/L	Q3 4.35 - 4.86 N Quantile: 332 N Cases: 40	OR	
	SGA N Total: 1659		DHA n-3 Measure: Biomarker n-3 Units: mg/L	Q4 4.88 - 5.54 N Quantile: 332 N Cases: 39	OR Estimate: 0.96 95% CI(0.6, 1.54)	
	SGA N Total: 1659		DHA n-3 Measure: Biomarker n-3 Units: mg/L	Q5 >=5.54 - N Quantile: 332 N Cases: 40	OR Estimate: 0.99 95% CI(0.62, 4.59)	
	SGA N Total: 1659		EPA n-3 Measure: Biomarker n-3 Units: mg/L	Q1 <0.33 - N Quantile: 332 N Cases: 42	OR Estimate: 2.09 95% CI(1.32, 3.3)	
	SGA N Total: 1659		EPA n-3 Measure: Biomarker n-3 Units: mg/L	Q2 0.33 - 0.46 N Quantile: 332 N Cases: 44	OR Estimate: 1.42 95% CI(0.88, 2.31)	
	SGA N Total: 1659		EPA n-3 Measure: Biomarker n-3 Units: mg/L	Q3 0.46 - 0.58 N Quantile: 332 N Cases: 32	OR	
	SGA N Total: 1659		EPA n-3 Measure: Biomarker n-3 Units: mg/L	Q4 0.58 - 0.81 N Quantile: 332 N Cases: 32	OR Estimate: 0.98 95% CI(0.59, 1.64)	
	SGA N Total: 1659		EPA n-3 Measure: Biomarker n-3 Units: mg/L	Q5 >=0.81 - N Quantile: 332 N Cases: 36	OR Estimate: 1.13 95% CI(0.68, 1.87)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Standl, et al., 2014 ¹⁷⁷ Study name: LISApplus Study dates: Recruitment 1997-1999 Study design: Observational prospective Location: Germany Funding source / conflict: Government Follow-up: 10 years	Study Population: Healthy infants Infants enrolled 436 Infants completers 243 Mother age: 32.7 (3.9) NR Infant age: Birth (NR) NR Race of Mother: NR (100)	Inclusion Criteria: NR Exclusion Criteria: Neonates displaying at least one of the following criteria: preterm birth (maturity <37 gestational weeks), low birth weight (<2,500 g), congenital malformation, symptomatic neonatal infection, antibiotic medication, hospitalization or intensive medical care during neonatal period. In addition, newborns from mothers with immune-related diseases (autoimmune disorders, diabetes, hepatitis B), on long-term medication or who abuse drugs and/or alcohol, and newborns from parents with a nationality other than German or who were not born in Germany, were excluded.	Adjustments: Parental education, sex, time of follow-up (2 yr, 6 yr or 10 yr for eczema; 6 yr and 10 yr for asthma, hay fever/allergic rhinitis and aeroallergen sensitization), age, maternal age at birth, parental atopy, total sum of fatty acids

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Standl 2014 ¹⁷⁷	Aeroallergen sensitization N Total: 243	10 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 43	OR Estimate: 1.03 95% CI(0.87, 1.23)	
	Aeroallergen sensitization N Total: 243	10 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 43	OR Estimate: 0.82 95% CI(0.56, 1.22)	
	Aeroallergen sensitization N Total: 277	6 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 24	OR Estimate: 1.03 95% CI(0.85, 1.25)	
	Aeroallergen sensitization N Total: 277	6 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 24	OR Estimate: 0.94 95% CI(0.61, 1.44)	
	Asthma N Total: 243	10 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 5	OR Estimate: 1.18 95% CI(0.79, 1.75)	
	Asthma N Total: 243	10 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 5	OR Estimate: 0.77 95% CI(0.29, 2.04)	
	Asthma N Total: 277	6 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 3	OR Estimate: 0.83 95% CI(0.48, 1.44)	
	Asthma N Total: 277	6 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 3	OR Estimate: 1.75 95% CI(0.73, 4.21)	
	Eczema N Total: 243	10 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 7	OR Estimate: 0.76 95% CI(0.52, 1.12)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Eczema N Total: 243	10 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 7	OR Estimate: 1.31 95% CI(0.63, 2.71)	
	Eczema N Total: 277	6 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 14	OR Estimate: 1.18 95% CI(0.95, 1.48)	
	Eczema N Total: 277	6 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 14	OR Estimate: 0.75 95% CI(0.45, 1.25)	
	Eczema N Total: 280	2 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 15	OR Estimate: 0.99 95% CI(0.78, 1.25)	
	Eczema N Total: 280	2 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 15	OR Estimate: 0.97 95% CI(0.58, 1.63)	
	Hay fever or allergic rhinitis N Total: 243	10 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 13	OR Estimate: 1 95% CI(0.77, 1.3)	
	Hay fever or allergic rhinitis N Total: 243	10 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 13	OR Estimate: 0.84 95% CI(0.47, 1.51)	
	Hay fever or allergic rhinitis N Total: 277	6 y	n-3 LC-PUFA n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 3	OR Estimate: 0.96 95% CI(0.6, 1.56)	
	Hay fever or allergic rhinitis N Total: 277	6 y	n-6/n-3 ratio n-3 Measure: Cord blood serum fatty acids n-3 Units: percentage of total fatty acids	All N Cases: 3	OR Estimate: 0.75 95% CI(0.27, 2.1)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Steer, et al., 2013 ¹⁶⁴ Study name: Avon Longitudinal Study of Parents and Children (ALSPAC) Study dates: 1991-2000 Study design: Observational prospective Location: UK Funding source / conflict: Government Follow-up: 8 years	Study Population: Healthy infants Healthy pregnant women Pregnant enrolled 14,541 Infants completers 2,839 Mother age: 29.33 (4.48) Infant age: birth Race of Mother: White European (98.8) Black (0.6) Asian (0.6)	Inclusion Criteria: pregnant women with expected delivery date between 4/91 and 12/92 in Bristol UK Exclusion Criteria: Not reported	Adjustments: Maternal age, education, ethnicity, alcohol consumption and smoking; partner status, housing tenure, crowding index, parity, preterm gestation (<37 wk), low birth weight (<2500 g), multiple births, sex, breastfeeding, and measures of adversity (in pregnancy and during the first 2 y after birth) and child stimulation (both from the home environment and maternal interaction with the child)

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Steer 2013 ¹⁶⁴	IQ N Total: 2839	7 years	AA n-3 Measure: maternal erythrocyte	Highest to other 3	Coefficient Estimate: -1.18 95% CI(-2.53, 0.18)	
	IQ N Total: 2839	7 years	AA n-3 Measure: maternal erythrocyte	Lowest to other 3	Coefficient Estimate: -1.54 95% CI(-2.91, -0.14)	
	IQ N Total: 2839	7 years	DHA n-3 Measure: maternal erythrocyte	Highest to other 3	Coefficient Estimate: -0.18 95% CI(-1.52, 1.17)	
	IQ N Total: 2839	7 years	DHA n-3 Measure: maternal erythrocyte	Lowest to other 3	Coefficient Estimate: -1.52 95% CI(-2.91, -0.14)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Strom, et al., 2009⁹²</p> <p>Study name: Danish National Birth Cohort</p> <p>Study dates: 1996-2002</p> <p>Study design: Observational prospective</p> <p>Location: Denmark</p> <p>Funding source / conflict: Government, Multiple foundations and Societies, Funding Affiliations trade group, March of Dimes</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 86,453 Pregnant withdrawals 32,251 Pregnant completers 54,202</p> <p>Pregnant age: not reported (not reported) not reported</p> <p>Race of Mother: NR (100%)</p>	<p>Inclusion Criteria: All pregnant women living in Denmark between 1996 and 2002, who were fluent in Danish</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: Total energy intake, pre-pregnant BMI, maternal age, parity, alcohol intake, smoking, occupation, education, homeownership, marital status, social support, and history of previous depression</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Strom 2009 ⁹²	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q1 9.1 N Cases: 16	OR Estimate: 0.96 95% CI(0.51, 1.78)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q2 14.1 N Cases: 16	OR Estimate: 1.03 95% CI(0.55, 1.92)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q3 18.1 N Cases: 11	OR Estimate: 0.73 95% CI(0.36, 1.48)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q4 22.2 N Cases: 19	OR Estimate: 1.33 95% CI(0.74, 2.39)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q5 27 N Cases: 17	OR Estimate: 1.21 95% CI(0.66, 2.21)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q6 32.7 N Cases: 23	OR Estimate: 1.65 95% CI(0.95, 2.88)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q7 39.6 N Cases: 18	OR Estimate: 1.3 95% CI(0.72, 2.36)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q8 48.4 N Cases: 11	OR Estimate: 0.79 95% CI(0.39, 1.59)	
	PPD admission		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q9+Q10 72.8 N Cases: 28	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q1 9.1 N Cases: 110	OR Estimate: 1.24 95% CI(0.96, 1.61)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q2 14.1 N Cases: 97	OR Estimate: 1.17 95% CI(0.9, 1.53)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q3 18.1 N Cases: 82	OR Estimate: 0.99 95% CI(0.75, 1.31)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q4 22.2 N Cases: 102	OR Estimate: 1.29 95% CI(0.99, 1.68)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q5 27 N Cases: 83	OR Estimate: 1.09 95% CI(0.83, 1.44)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q6 32.7 N Cases: 85	OR Estimate: 1.11 95% CI(0.84, 1.46)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q7 39.6 N Cases: 80	OR Estimate: 1.04 95% CI(0.79, 1.38)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q8 48.4 N Cases: 70	OR Estimate: 0.89 95% CI(0.67, 1.2)	
	PPD prescription		n-3 PUFA intake n-3 Measure: FFQ n-3 Units: mg/d	Q9+Q10 72.8 N Cases: 157	OR	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Sun, et al., 2010¹³¹</p> <p>Study name: Danish National Birth Cohort</p> <p>Study dates: Recruitment March 1996 to November 2002</p> <p>Study design: Observational prospective</p> <p>Location: Denmark</p> <p>Funding source / conflict: Government</p> <p>Follow-up: 10.8 years (median 7.8 years)</p>	<p>Study Population: Healthy infants</p> <p>Infants enrolled 65,754 Infants completers 65754</p> <p>Infant age: birth</p> <p>Race of Mother: NR (NR)</p>	<p>Inclusion Criteria: live-born singletons whose mothers provided information on fish intake from food frequency questionnaire</p> <p>Exclusion Criteria: children with missing information on maternal smoking and parity, children who died during the neonatal period, and children born to mothers with an unlikely high (>16,700 kJ/day) or low (<4200 kJ/day) intake of energy during pregnancy</p>	<p>Adjustments: Energy intake, sex, gestational age, parity, time breastfeeding, maternal age, SES, pre-pregnancy BMI, smoking status at recruitment, maternal history of epilepsy</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Sun, 2010 ¹³¹	Epilepsy	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 12,245 N Cases: 126	Incidence rate ratio (IRR) Estimate: 1.33 95% CI(1.02, 1.74)	
	Epilepsy	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 12,318 N Cases: 97	Incidence rate ratio (IRR)	
	Epilepsy	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 12,332 N Cases: 104	Incidence rate ratio (IRR) Estimate: 1.05 95% CI(0.79, 1.38)	
	Epilepsy	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 12,421 N Cases: 102	Incidence rate ratio (IRR) Estimate: 1.05 95% CI(0.81, 1.41)	
	Epilepsy	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 4,528 N Cases: 34	Incidence rate ratio (IRR) Estimate: 1.01 95% CI(0.68, 1.49)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Supplements during pregnancy n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	377 N Quantile: 4,528 N Cases: 34	Incidence rate ratio (IRR) Estimate: 1.01 95% CI(0.68, 1.49)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: FFQ n-3 Units: mg/day	N Quantile: 11,910 N Cases: 128	Incidence rate ratio (IRR) Estimate: 1.28 95% CI(0.98, 1.67)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	Q1 117 N Quantile: 11,910 N Cases: 128	Incidence rate ratio (IRR) Estimate: 1.28 95% CI(0.98, 1.67)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	Q2 207 N Quantile: 12,332 N Cases: 104	Incidence rate ratio (IRR) Estimate: 1.05 95% CI(0.79, 1.38)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	Q3 308 N Quantile: 12,318 N Cases: 97	Incidence rate ratio (IRR)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	Q4 451 N Quantile: 12,421 N Cases: 102	Incidence rate ratio (IRR) Estimate: 1.05 95% CI(0.81, 1.41)	
	Epilepsy N Total: 65754	Up to 10.8 years, mean 7.8 years	Total n-3 LCPUFA n-3 Measure: Maternal food frequency questionnaire n-3 Units: mg/day	Q5 817 N Quantile: 12,245 N Cases: 126	Incidence rate ratio (IRR) Estimate: 1.33 95% CI(1.02, 1.74)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Thijs, et al., 2011¹⁷⁸</p> <p>Study name: KOALA Birth Cohort Study</p> <p>Study dates: 2003</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Government, None</p> <p>Follow-up: 2 years</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 312 Pregnant completers 304</p> <p>Infants enrolled 312 Infants completers 304</p> <p>Pregnant age: 33.3 (3.9) NR</p> <p>Race of Mother: NR (100)</p>	<p>Inclusion Criteria: availability of complete baseline data from the 34 weeks pregnancy questionnaire and availability of a breast milk sample.</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: Recruitment group, maternal age, maternal education, infant's gender, number of older siblings and their atopic history, parental atopic history, maternal smoking during pregnancy and/or smoking in presence of the infant, place of birth, season of breast milk collection, duration and exclusivity of breastfeeding, maternal n-3 fatty acids supplement use, maternal probiotic supplement use, maternal probiotic dairy use, maternal antibiotic use during lactation, infant's antibiotic use, vaccination schedule, dampness of the home, pet animals in the home.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Thijs 2011 ¹⁷⁸	Allergic sensitisation N Total: 204	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt1 0.3-0.56 N Quantile: 41 N Cases: 10	OR	
	Allergic sensitisation N Total: 204	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt2 0.56-0.65 N Quantile: 44 N Cases: 13	OR Estimate: 1.29 95% CI(0.45, 3.68)	
	Allergic sensitisation N Total: 204	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt3 0.65-0.78 N Quantile: 53 N Cases: 15	OR Estimate: 1.32 95% CI(0.47, 3.72)	
	Allergic sensitisation N Total: 204	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt4 0.78-2.55 N Quantile: 66 N Cases: 13	OR Estimate: 0.89 95% CI(0.32, 2.5)	
	Allergic sensitisation N Total: 220	1 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt1 0.3-0.56 N Quantile: 49 N Cases: 8	OR	
	Allergic sensitisation N Total: 220	1 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt2 0.56-0.65 N Quantile: 45 N Cases: 6	OR Estimate: 0.8 95% CI(0.21, 3.08)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic sensitisation N Total: 220	1 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt3 0.65-0.78 N Quantile: 58 N Cases: 9	OR Estimate: 0.68 95% CI(0.21, 2.2)	
	Allergic sensitisation N Total: 220	1 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt4 0.78-2.55 N Quantile: 68 N Cases: 5	OR Estimate: 0.17 95% CI(0.04, 0.77)	
	Atopic dermatitis N Total: 207	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: NR	All N Cases: 31	OR Estimate: 0.33 95% CI(0.13, 0.87)	
	Atopic dermatitis N Total: 207	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt1 0.3-0.56 N Quantile: 43 N Cases: 10	OR	
	Atopic dermatitis N Total: 207	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt2 0.56-0.65 N Quantile: 44 N Cases: 7	OR Estimate: 0.83 95% CI(0.27, 2.57)	
	Atopic dermatitis N Total: 207	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt3 0.65-0.78 N Quantile: 54 N Cases: 8	OR Estimate: 0.46 95% CI(0.13, 1.59)	
	Atopic dermatitis N Total: 207	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt4 0.78-2.55 N Quantile: 66 N Cases: 6	OR Estimate: 0.34 95% CI(0.12, 0.97)	
	Eczema N Total: 304	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: NR	All N Cases: 95	OR Estimate: 0.6 95% CI(0.37, 0.98)	
	Eczema N Total: 304	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt1 0.3-0.56 N Quantile: 72 N Cases: 26	OR	
	Eczema N Total: 304	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt2 0.56-0.65 N Quantile: 68 N Cases: 21	OR Estimate: 0.8 95% CI(0.37, 1.71)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Eczema N Total: 304	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt3 0.65-0.78 N Quantile: 74 N Cases: 24	OR Estimate: 0.89 95% CI(0.43, 1.88)	
	Eczema N Total: 304	2 y	Main n-3 LCPs (EPA+DHA+DPA) n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: weight-percentage (wt%, mg/100 mg) of total breast milk fat	Qt4 0.78-2.55 N Quantile: 90 N Cases: 24	OR Estimate: 0.62 95% CI(0.3, 1.29)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
Valent, et al., 2013 ¹³² Study dates: 2007-2011 Study design: Observational prospective Location: Italy Funding source / conflict: Government	Study Population: Healthy infants Healthy pregnant women Pregnant enrolled 900 Pregnant completers 767 Infants enrolled 767 Infants completers 632 Pregnant age: 33.3 (4.3) Infant age: Birth Race of Mother: NR (100)	Inclusion Criteria: Permanent residents of the study areas for at least 2 years, at least 18 years of age, and had no absence from the study area for more than 6 weeks during pregnancy, no history of drug abuse, no serious health problems or complications of pregnancy, and no twin gestation Exclusion Criteria: Preterm births (<37 weeks of gestational age), babies with congenital malformations or severe perinatal problems, and those with severe health problems that presented postnatally and potentially compromised their neurological development	Adjustments: Fish intake, fatty acids in maternal serum and proportion of PUFAs, sex, birth weight, maternal IQ, weight gain during pregnancy, marital status at delivery, SES index, number of children living in home, alcohol intake during pregnancy, breastfeeding history, child intake of fish until age 18 months, and daycare attendance at age 18 months

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Valent 2013 ¹³²	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	AA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.95
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	ALA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.35
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	DHA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.49
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	DPA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.28
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	EPA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.99
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	Total n-3s n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.66
	Bayley Scales of Infant Dev., Version 3, Cognitive Scale N Total: 606	18 months	n-6/n-3 n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.82
	Motor function N Total: 606	18 months	AA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.79
	Motor function N Total: 606	18 months	ALA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.56
	Motor function N Total: 606	18 months	DHA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.51

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Motor function N Total: 606	18 months	DPA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.22
	Motor function N Total: 606	18 months	EPA n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.31
	Motor function N Total: 606	18 months	Total n-3s n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.41
	Motor function N Total: 606	18 months	n-6/n-3 n-3 Measure: Maternal prenatal serum n-3 Units: mg/ml	All	Coefficient	P value: P=0.61

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Wijga, et al., 2006¹⁷⁵</p> <p>Study name: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study</p> <p>Study dates: 1995-2000</p> <p>Study design: Observational prospective</p> <p>Location: Netherlands</p> <p>Funding source / conflict: Industry, Government</p> <p>Follow-up: 4 years</p>	<p>Study Population: NR</p> <p>Pregnant enrolled 276 Pregnant withdrawals 11 Pregnant completers 265</p> <p>Infants enrolled 276 Infants withdrawals 11 Infants completers 265</p> <p>Pregnant age: 31.0 (3.9) NR</p> <p>Race of Mother: NR (100)</p>	<p>Inclusion Criteria: Mothers reporting at least 1 of the following: (a history of) asthma, current hay fever, current allergy for pets, or current allergy for house dust or house dust mite were defined as allergic, and mothers reporting that they had none of these were defined as non-allergic.</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: Sex, number of older siblings, maternal age, maternal smoking during pregnancy, and maternal body mass index before pregnancy</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Wijga 2006 ¹⁷⁵	Asthma N Total: 158	4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.74 95% CI(0.37, 1.47)	
	Asthma N Total: 158	4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.93 95% CI(0.5, 1.35)	
	Asthma N Total: 158	4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.5 95% CI(0.22, 1.13)	
	Asthma N Total: 158	4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.39 95% CI(0.15, 0.99)	
	Asthma N Total: 158	4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.79 95% CI(0.48, 1.29)	
	Asthma N Total: 158	4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.72 95% CI(0.41, 1.26)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Asthma N Total: 158	4 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 14	OR Estimate: 0.39 95% CI(0.16, 1)	
	Eczema N Total: 158	1 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.62 95% CI(0.36, 1.01)	
	Eczema N Total: 158	1 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.67 95% CI(0.39, 1.2)	
	Eczema N Total: 158	1 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.74 95% CI(0.45, 1.21)	
	Eczema N Total: 158	1 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.79 95% CI(0.5, 1.23)	
	Eczema N Total: 158	1 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 1.06 95% CI(0.83, 1.37)	
	Eczema N Total: 158	1 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.9 95% CI(0.65, 1.26)	
	Eczema N Total: 158	1 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 26	OR Estimate: 0.82 95% CI(0.52, 1.27)	
	Eczema N Total: 158	4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.82 95% CI(0.48, 1.39)	
	Eczema N Total: 158	4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.82 95% CI(0.5, 1.35)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Eczema N Total: 158	4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.84 95% CI(0.54, 1.3)	
	Eczema N Total: 158	4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.99 95% CI(0.7, 1.41)	
	Eczema N Total: 158	4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.91 95% CI(0.68, 1.23)	
	Eczema N Total: 158	4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.9 95% CI(0.65, 1.26)	
	Eczema N Total: 158	4 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 27	OR Estimate: 0.81 95% CI(0.52, 1.26)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.81 95% CI(0.45, 1.48)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.66 95% CI(0.35, 1.25)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.53 95% CI(0.27, 1.04)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.67 95% CI(0.37, 1.19)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.72 95% CI(0.46, 1.14)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.67 95% CI(0.41, 1.1)	
	Persistent symptoms (eczema at 1 year as well as eczema and/or asthma at age 4 years) N Total: 158	1 y/4 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 20	OR Estimate: 0.51 95% CI(0.25, 1.03)	
	Sensitization and symptoms N Total: 81	4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 1.23 95% CI(0.53, 2.82)	
	Sensitization and symptoms N Total: 81	4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.7 95% CI(0.3, 1.63)	
	Sensitization and symptoms N Total: 81	4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.48 95% CI(0.17, 1.31)	
	Sensitization and symptoms N Total: 81	4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.78 95% CI(0.36, 1.69)	
	Sensitization and symptoms N Total: 81	4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.52 95% CI(0.23, 1.18)	
	Sensitization and symptoms N Total: 81	4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.56 95% CI(0.26, 1.22)	
	Sensitization and symptoms N Total: 81	4 y	n-3 LCP/n-6 LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 10	OR Estimate: 0.38 95% CI(0.12, 1.22)	
	Sensitization N Total: 52	4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 0.62 95% CI(0.27, 1.39)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Sensitization N Total: 52	4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 2.43 95% CI(1.01, 5.88)	
	Sensitization N Total: 52	4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 1.11 95% CI(0.86, 1.42)	
	Sensitization N Total: 52	4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 1.1 95% CI(0.9, 1.34)	
	Sensitization N Total: 52	4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 1.22 95% CI(0.92, 1.62)	
	Sensitization N Total: 52	4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 1.13 95% CI(0.9, 1.43)	
	Sensitization N Total: 52	4 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 16	OR Estimate: 1.29 95% CI(0.85, 1.95)	
	Sensitization N Total: 81	4 y	AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 0.85 95% CI(0.5, 1.46)	
	Sensitization N Total: 81	4 y	ALA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 0.81 95% CI(0.49, 1.35)	
	Sensitization N Total: 81	4 y	All n-3 n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 0.86 95% CI(0.52, 1.41)	
	Sensitization N Total: 81	4 y	DHA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 0.89 95% CI(0.57, 1.38)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Sensitization N Total: 81	4 y	EPA/AA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 1.02 95% CI(0.71, 1.46)	
	Sensitization N Total: 81	4 y	EPA n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 0.85 95% CI(0.55, 1.32)	
	Sensitization N Total: 81	4 y	n-3LCP/n-6LCP n-3 Measure: Breast milk fatty acid content, median wt% (interquartile range) n-3 Units: per interquartile range increase in breast milk FA content (wt%)	All N Cases: 32	OR Estimate: 1.12 95% CI(0.7, 1.77)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Yoshihiro Miyake, et al., 2006⁹³</p> <p>Study name: Osaka maternal and child health study</p> <p>Study dates: 2001-2003</p> <p>Study design: Observational prospective</p> <p>Location: Japan</p> <p>Funding source / conflict: Government, Multiple foundations and Societies, None</p>	<p>Study Population: Healthy pregnant women</p> <p>Pregnant enrolled 1002 Pregnant withdrawals 137 Pregnant completers 865</p> <p>Pregnant age: age reported in categories</p> <p>Race of Mother: Asian (100%)</p>	<p>Inclusion Criteria: women who became pregnant in Neyagawa City, Osaka Prefecture, Japan</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: Age, gestation, parity, cigarette smoking, family structure, family income, education, changes in diet in the previous month, season when data at baseline were collected, body mass index, time of delivery before the second survey, medical problems in pregnancy, baby's sex and baby's birthweight</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Miyake 2006 ⁹³			DHA n-3 Measure: FFQ n-3 Units: g/day	Q1 0.16	OR	
			DHA n-3 Measure: FFQ n-3 Units: g/day	Q2 0.26	OR Estimate: 0.76 95% CI(0.44, 1.32)	
			DHA n-3 Measure: FFQ n-3 Units: g/day	Q3 0.34	OR Estimate: 0.62 95% CI(0.34, 1.09)	
			DHA n-3 Measure: FFQ n-3 Units: g/day	Q4 0.5	OR Estimate: 0.85 95% CI(0.49, 1.46)	
			EPA n-3 Measure: FFQ n-3 Units: g/day	Q1 0.08	OR	
			EPA n-3 Measure: FFQ n-3 Units: g/day	Q2 0.15	OR Estimate: 0.93 95% CI(0.54, 1.6)	
			EPA n-3 Measure: FFQ n-3 Units: g/day	Q3 0.21	OR Estimate: 0.81 95% CI(0.46, 1.42)	
			EPA n-3 Measure: FFQ n-3 Units: g/day	Q4 0.32	OR Estimate: 0.89 95% CI(0.51, 1.55)	
			n-3 FA n-3 Measure: FFQ n-3 Units: g/day	Q1 1.6	OR	
		n-3 FA n-3 Measure: FFQ n-3 Units: g/day	Q2 2.1	OR Estimate: 0.68 95% CI(0.39, 1.18)		

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
			n-3 FA n-3 Measure: FFQ n-3 Units: g/day	Q3 2.4	OR Estimate: 0.58 95% CI(0.33, 1.02)	
			n-3 FA n-3 Measure: FFQ n-3 Units: g/day	Q4 3	OR Estimate: 0.9 95% CI(0.53, 1.53)	

Author, Year, Study, Location, Funding Source, Follow-up	Population and participant information	Inclusion and Exclusion Criteria	Adjustment
<p>Yu, et al., 2015¹⁸⁵</p> <p>Study dates: Participants recruited between June 2009 and September 2010</p> <p>Study design: Observational prospective</p> <p>Location: NR</p> <p>Funding source / conflict: Industry, Government</p>	<p>Study Population: Healthy infants Healthy pregnant women</p> <p>Infants enrolled 1162 Infants completers 960</p> <p>Pregnant age: NR (NR) NR</p> <p>Race of Mother: NR (100%)</p>	<p>Inclusion Criteria: Participants were mother–child pairs in the Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort.</p> <p>Exclusion Criteria: NR</p>	<p>Adjustments: In the models, we adjusted for maternal characteristics including maternal age, ethnicity, gravidity, education level and energy intake. The same was done for infant characteristics including sex, birth weight, gestational age, duration of breast-feeding, family history of allergic diseases (which includes allergic rhinitis, eczema and asthma in first-degree relatives of the children (i.e. father, mother and/or sibling), exposure to environmental tobacco smoking, child day care attendance and having a cat or dog at home up to 18 months of age.</p>

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Yu 2015 ¹⁸⁵	Allergic sensitisation N Total: 728	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =1.0 N Quantile: NR N Cases: NR	OR	
	Allergic sensitisation N Total: 728	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.11-0.18 N Quantile: NR N Cases: NR	OR Estimate: 0.8 95% CI(0.43, 1.49)	
	Allergic sensitisation N Total: 728	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.19-0.27 N Quantile: NR N Cases: NR	OR Estimate: 0.92 95% CI(0.51, 1.68)	
	Allergic sensitisation N Total: 728	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.28 N Quantile: NR N Cases: NR	OR Estimate: 0.85 95% CI(0.46, 1.55)	
	Allergic sensitisation N Total: 728	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =3.60 N Quantile: NR N Cases: NR	OR	
	Allergic sensitisation N Total: 728	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 3.16-4.59 N Quantile: NR N Cases: NR	OR Estimate: 0.9 95% CI(0.48, 1.65)	
	Allergic sensitisation N Total: 728	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 4.60-5.63 N Quantile: NR N Cases: NR	OR Estimate: 0.73 95% CI(0.38, 1.40)	
	Allergic sensitisation N Total: 728	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =5.64 N Quantile: NR N Cases: NR	OR Estimate: 1.24 95% CI(0.69, 2.24)	
	Allergic sensitisation N Total: 728	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =0.35 N Quantile: NR N Cases: NR	OR	
	Allergic sensitisation N Total: 728	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.36-0.51 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.57, 2.21)	
	Allergic sensitisation N Total: 728	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.52-0.82 N Quantile: NR N Cases: NR	OR Estimate: 1.26 95% CI(0.65, 2.47)	
	Allergic sensitisation N Total: 728	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.83 N Quantile: NR N Cases: NR	OR Estimate: 1.82 95% CI(0.94, 3.50)	
	Allergic sensitisation N Total: 728	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =5.00 N Quantile: NR N Cases: NR	OR	
	Allergic sensitisation N Total: 728	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 5.01-6.18 N Quantile: NR N Cases: NR	OR Estimate: 0.91 95% CI(0.48, 1.72)	
	Allergic sensitisation N Total: 728	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 6.19-7.49 N Quantile: NR N Cases: NR	OR Estimate: 0.83 95% CI(0.43, 1.58)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Allergic sensitisation N Total: 728	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =7.50 N Quantile: NR N Cases: NR	OR Estimate: 1.41 95% CI(0.77, 2.58)	
	Allergic sensitisation N Total: 728	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =4.52 N Quantile: NR N Cases: NR	OR	
	Allergic sensitisation N Total: 728	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 4.53-5.49 N Quantile: NR N Cases: NR	OR Estimate: 0.6 95% CI(0.33, 1.10)	
	Allergic sensitisation N Total: 728	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 5.50-6.94 N Quantile: NR N Cases: NR	OR Estimate: 0.67 95% CI(0.37, 1.21)	
	Allergic sensitisation N Total: 728	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =6.95 N Quantile: NR N Cases: NR	OR Estimate: 0.66 95% CI(0.36, 1.22)	
	Eczema N Total: 833	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =1.0 N Quantile: NR N Cases: NR	OR	
	Eczema N Total: 833	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.11-0.18 N Quantile: NR N Cases: NR	OR Estimate: 0.87 95% CI(0.50, 1.51)	
	Eczema N Total: 833	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.19-0.27 N Quantile: NR N Cases: NR	OR Estimate: 1.07 95% CI(0.64, 1.81)	
	Eczema N Total: 833	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.28 N Quantile: NR N Cases: NR	OR Estimate: 0.87 95% CI(0.51, 1.47)	
	Eczema N Total: 833	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =3.60 N Quantile: NR N Cases: NR	OR	
	Eczema N Total: 833	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 3.16-4.59 N Quantile: NR N Cases: NR	OR Estimate: 1.02 95% CI(0.61, 1.70)	
	Eczema N Total: 833	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 4.60-5.63 N Quantile: NR N Cases: NR	OR Estimate: 0.61 95% CI(0.35, 1.07)	
	Eczema N Total: 833	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =5.64 N Quantile: NR N Cases: NR	OR Estimate: 0.8 95% CI(0.47, 1.35)	
	Eczema N Total: 833	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =0.35 N Quantile: NR N Cases: NR	OR	
	Eczema N Total: 833	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.36-0.51 N Quantile: NR N Cases: NR	OR Estimate: 1.14 95% CI(0.64, 2.04)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
Eczema N Total: 833		Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.52-0.82 N Quantile: NR N Cases: NR	OR Estimate: 1.07 95% CI(0.60, 1.89)	
Eczema N Total: 833		Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.83 N Quantile: NR N Cases: NR	OR Estimate: 1.2 95% CI(0.68, 2.13)	
Eczema N Total: 833		Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =5.00 N Quantile: NR N Cases: NR	OR	
Eczema N Total: 833		Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 5.01-6.18 N Quantile: NR N Cases: NR	OR Estimate: 1.02 95% CI(0.60, 1.74)	
Eczema N Total: 833		Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 6.19-7.49 N Quantile: NR N Cases: NR	OR Estimate: 0.67 95% CI(0.38, 1.18)	
Eczema N Total: 833		Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =7.50 N Quantile: NR N Cases: NR	OR Estimate: 0.93 95% CI(0.55, 1.60)	
Eczema N Total: 833		Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 1.9-4.5 N Quantile: NR N Cases: NR	OR	
Eczema N Total: 833		Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 4.6-5.4 N Quantile: NR N Cases: NR	OR Estimate: 0.55 95% CI(0.32, 0.97)	
Eczema N Total: 833		Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 5.5-6.9 N Quantile: NR N Cases: NR	OR Estimate: 1.19 95% CI(0.72, 1.97)	
Eczema N Total: 833		Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 7.0-16.6 N Quantile: NR N Cases: NR	OR Estimate: 1.21 95% CI(0.71, 2.06)	
Rhinitis N Total: 808		Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =1.0 N Quantile: NR N Cases: NR	OR	
Rhinitis N Total: 808		Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.11-0.18 N Quantile: NR N Cases: NR	OR Estimate: 1.18 95% CI(0.74, 1.89)	
Rhinitis N Total: 808		Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.19-0.27 N Quantile: NR N Cases: NR	OR Estimate: 0.95 95% CI(0.59, 1.52)	
Rhinitis N Total: 808		Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.28 N Quantile: NR N Cases: NR	OR Estimate: 0.86 95% CI(0.54, 1.38)	
Rhinitis N Total: 808		Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =3.60 N Quantile: NR N Cases: NR	OR	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Rhinitis N Total: 808	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 3.16-4.59 N Quantile: NR N Cases: NR	OR Estimate: 1.53 95% CI(0.94, 2.50)	
	Rhinitis N Total: 808	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 4.60-5.63 N Quantile: NR N Cases: NR	OR Estimate: 1.97 95% CI(1.22, 3.21)	
	Rhinitis N Total: 808	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =5.64 N Quantile: NR N Cases: NR	OR Estimate: 1.42 95% CI(0.87, 2.32)	
	Rhinitis N Total: 808	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =0.35 N Quantile: NR N Cases: NR	OR	
	Rhinitis N Total: 808	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.36-0.51 N Quantile: NR N Cases: NR	OR Estimate: 1.09 95% CI(0.68, 1.77)	
	Rhinitis N Total: 808	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.52-0.82 N Quantile: NR N Cases: NR	OR Estimate: 1.02 95% CI(0.63, 1.66)	
	Rhinitis N Total: 808	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.83 N Quantile: NR N Cases: NR	OR Estimate: 1.04 95% CI(0.64, 1.69)	
	Rhinitis N Total: 808	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =5.00 N Quantile: NR N Cases: NR	OR	
	Rhinitis N Total: 808	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 5.01-6.18 N Quantile: NR N Cases: NR	OR Estimate: 1.56 95% CI(0.96, 2.54)	
	Rhinitis N Total: 808	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 6.19-7.49 N Quantile: NR N Cases: NR	OR Estimate: 1.67 95% CI(1.03, 2.70)	
	Rhinitis N Total: 808	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =7.50 N Quantile: NR N Cases: NR	OR Estimate: 1.34 95% CI(0.81, 2.21)	
	Rhinitis N Total: 808	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 1.9-4.5 N Quantile: NR N Cases: NR	OR	
	Rhinitis N Total: 808	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 4.6-5.4 N Quantile: NR N Cases: NR	OR Estimate: 1.11 95% CI(.7, 1.75)	
	Rhinitis N Total: 808	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 5.5-6.9 N Quantile: NR N Cases: NR	OR Estimate: 1.34 95% CI(.85, 2.11)	
	Rhinitis N Total: 808	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 7.0-16.6 N Quantile: NR N Cases: NR	OR Estimate: 0.66 95% CI(0.40, 1.10)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheezing N Total: 859	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =1.0 N Quantile: NR N Cases: NR	OR	
	Wheezing N Total: 859	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.11-0.18 N Quantile: NR N Cases: NR	OR Estimate: 1.22 95% CI(0.61, 2.44)	
	Wheezing N Total: 859	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.19-0.27 N Quantile: NR N Cases: NR	OR Estimate: 1.77 95% CI(0.91, 3.46)	
	Wheezing N Total: 859	Up to 18 months	A-linolenic acid n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.28 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.56, 2.24)	
	Wheezing N Total: 859	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =3.60 N Quantile: NR N Cases: NR	OR	
	Wheezing N Total: 859	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 3.16-4.59 N Quantile: NR N Cases: NR	OR Estimate: 0.95 95% CI(0.49, 1.86)	
	Wheezing N Total: 859	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 4.60-5.63 N Quantile: NR N Cases: NR	OR Estimate: 0.98 95% CI(0.49, 1.96)	
	Wheezing N Total: 859	Up to 18 months	DHA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =5.64 N Quantile: NR N Cases: NR	OR Estimate: 1.15 95% CI(0.60, 2.22)	
	Wheezing N Total: 859	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =0.35 N Quantile: NR N Cases: NR	OR	
	Wheezing N Total: 859	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 0.36-0.51 N Quantile: NR N Cases: NR	OR Estimate: 1.07 95% CI(0.52, 2.21)	
	Wheezing N Total: 859	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 0.52-0.82 N Quantile: NR N Cases: NR	OR Estimate: 1.19 95% CI(0.60, 2.36)	
	Wheezing N Total: 859	Up to 18 months	EPA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =0.83 N Quantile: NR N Cases: NR	OR Estimate: 1.2 95% CI(0.60, 2.39)	
	Wheezing N Total: 859	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 =5.00 N Quantile: NR N Cases: NR	OR	
	Wheezing N Total: 859	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 5.01-6.18 N Quantile: NR N Cases: NR	OR Estimate: 0.9 95% CI(0.45, 1.78)	
	Wheezing N Total: 859	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 6.19-7.49 N Quantile: NR N Cases: NR	OR Estimate: 1.09 95% CI(0.56, 2.13)	

Article	Outcome, Cohort size	Follow up Time	Exposure Intervention, n-3 measure, n-3 units	Quantile	Metric, Estimate and CI	P value
	Wheezing N Total: 859	Up to 18 months	n-3 PUFA n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 =7.50 N Quantile: NR N Cases: NR	OR Estimate: 1.12 95% CI(0.57, 2.2)	
	Wheezing N Total: 859	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q1 1.9-4.5 N Quantile: NR N Cases: NR	OR	
	Wheezing N Total: 859	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q2 4.6-5.4 N Quantile: NR N Cases: NR	OR Estimate: 0.7 95% CI(0.38, 1.30)	
	Wheezing N Total: 859	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q3 5.5-6.9 N Quantile: NR N Cases: NR	OR Estimate: 0.64 95% CI(0.34, 1.23)	
	Wheezing N Total: 859	Up to 18 months	n-6: n-3 PUFA ratio n-3 Measure: Maternal blood n-3 Units: % of total plasma fatty acids	Q4 7.0-16.6 N Quantile: NR N Cases: NR	OR Estimate: 0.63 95% CI(0.32, 1.25)	